Product Monograph

Including Patient Medication Information

LUTATHERA®

lutetium (^{177}Lu) oxodotreotide injection

Sterile Solution for Intravenous Infusion

370 MBq/mL at calibration

Therapeutic Radiopharmaceutical

Novartis Pharmaceuticals Canada Inc.

700 Saint-Hubert St., Suite 100
Montreal, Quebec
H2Y 0C1
www.novartis.ca

Date of Authorization:
2026-10-23

Control Number: 502581

LUTATHERA is a registered trademark

Recent Major Label Changes

1 Indications	12/2024
1 Indications, 1.1 Pediatrics	12/2024
4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment	12/2024
4 Dosage and Administration, 4.8 Radiation Dosimetry	12/2024
7 Warnings and Precautions, Renal	12/2024
7 Warnings and Precautions, 7.1.3 Pediatrics	12/2024

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes 2

Table of Contents 2

Part 1: Healthcare Professional Information 5

1 Indications 5

1.1 Pediatrics 5

1.2 Geriatrics 5

2 Contraindications 5

3 Serious Warnings and Precautions Box 5

4 Dosage and Administration 5

4.1 Dosing Considerations 6

4.2 Recommended Dose and Dosage Adjustment 6

4.4 Administration 9

4.7 Instructions for Preparation and Use of Radiopharmaceuticals 14

4.8 Radiation Dosimetry 14

5 Overdose 18

6 Dosage Forms, Strengths, Composition, and Packaging 18

6.1 Physical Characteristics 19

6.2 External Radiation 19

7 Warnings and Precautions 19

General 20

Carcinogenesis and Genotoxicity 20

Contamination 21
Endocrine and Metabolism 21
Hematologic 21
Hepatic/Biliary/Pancreatic 21
Radiation Exposure 22
Renal 22
Reproductive Health 23
Sensitivity/Resistance 23
7.1 Special Populations 24
7.1.1 Pregnancy 24
7.1.2 Breastfeeding 24
7.1.3 Pediatrics 24
7.1.4 Geriatrics 24
8 Adverse Reactions 25
8.1 Adverse Reaction Overview 25
8.2 Clinical Trial Adverse Reactions 25
8.2.1 Clinical Trial Adverse Reactions – Pediatrics 31
8.3 Less Common Clinical Trial Adverse Reactions 32
8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics 34
8.5 Post-Market Adverse Reactions 34
9 Drug Interactions 34
9.2 Drug Interactions Overview 34
9.4 Drug-Drug Interactions 34
9.5 Drug-Food Interactions 35
9.6 Drug-Herb Interactions 35
9.7 Drug-Laboratory Test Interactions 35
10 Clinical Pharmacology 35
10.1 Mechanism of Action 35
10.2 Pharmacodynamics 35
10.3 Pharmacokinetics 35
11 Storage, Stability and Disposal 37
12 Special Handling Instructions 37
Part 2: Scientific Information 39

13 Pharmaceutical Information 39
14 Clinical Trials 39
14.1 Clinical Trials by Indication 39
15 Microbiology 44
16 Non-Clinical Toxicology 44
Patient Medication Information 47

Part 1: Healthcare Professional Information

1 Indications

LUTATHERA® (lutetium (^{177}Lu) oxodotreotide injection) is indicated for:

- The treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults and adolescents 12 years of age and older with progressive disease.

1.1 Pediatrics

Pediatrics (< 12 years of age): The safety and efficacy of LUTATHERA in pediatrics <12 years of age have not been established. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric patients below 12 years of age.

1.2 Geriatrics

Geriatrics (> 65 years of age): Of the 1325 patients treated with LUTATHERA in clinical trials, 438 patients (33%) were 65 years and older (see 7.1.4 Geriatrics).

2 Contraindications

- Severe renal impairment (creatinine clearance < 30 mL/min);
- Established or suspected pregnancy (when pregnancy has not been excluded); and/or
- Hypersensitivity to the medicinal ingredient or to any of the excipients listed (see 6 Dosage Forms, Strengths, Composition and Packaging).

3 Serious Warnings and Precautions Box

- Radiopharmaceuticals should be used only by those healthcare professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.
- Acute and chronic renal toxicity can occur in patients treated with LUTATHERA (see 7 Warnings and Precautions). Cases of severe and life-threatening renal injury have been reported. Do not administer LUTATHERA to patients with severe renal impairment (creatinine clearance < 30 mL/min) (see 2 Contraindications).
- Myelodysplastic syndrome (MDS) and Acute Leukaemia (AL): Late-onset MDS and AL have been reported following treatment with LUTATHERA (see 7 Warnings and Precautions).

4 Dosage and Administration

LUTATHERA is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure (see 7 Warnings and Precautions). Use waterproof gloves and effective radiation shielding when handling LUTATHERA. LUTATHERA should be used by or under the control of healthcare professionals who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA (see 7

Warnings and Precautions and 7.1 Special Populations).

Before initiating treatment with LUTATHERA, presence of somatostatin receptor-positive tumours must be confirmed, preferably by somatostatin receptor imaging.

4.1 Dosing Considerations

LUTATHERA dosing instructions include provisions for:

- Use of concomitant medications for renal protection and mitigation of nausea and vomiting; and
- Dose modifications due to toxicity.

4.2 Recommended Dose and Dosage Adjustment

The recommended LUTATHERA dose in adults and adolescents (12 years of age and older) is:

- 7.4 GBq (200 mCi) as an intravenous infusion over approximately 30 minutes every 8 weeks for a total of 4 doses.

Monitoring Recommendations

Before each administration and during treatment with LUTATHERA, hematology (platelet count, white blood cell count and hemoglobin [Hb]), kidney function test (serum creatinine) and liver function test (alanine aminotransferase [ALT], aspartate aminotransferase [AST], serum albumin and bilirubin) should be performed to assess the patient's condition.

These laboratory tests should be performed shortly before each administration and 4 weeks after each dose of LUTATHERA. It is also recommended to perform these tests every 4 weeks for at least 3 months after the last infusion of LUTATHERA and then every 6 months thereafter, in order to be able to detect possible delayed adverse drug reactions (ADRs).

In the NETTER-P study, a 50% dose reduction following the first dose of LUTATHERA was recommended in 2 of 9 adolescent patients (22%) due to the estimated cumulative absorbed organ dose exceeding the threshold of 29 Gy for the kidneys and/or 2 Gy for the bone marrow (DCO 21 Aug 2023). Dosimetry monitoring of the kidneys and bone marrow of adolescent patients after the first dose of LUTATHERA is recommended. Healthcare professionals should consider dose reduction following the first dose of LUTATHERA if the estimated cumulative absorbed dose exceeds a threshold of 29 Gy for the kidneys and/or 2 Gy for the bone marrow.

Dose Modifications for Adverse Reactions

Management of severe or intolerable ADRs may require temporary dose interruption, extending the dosing interval from 8 weeks up to 16 weeks, dose reduction, or discontinuation of treatment with LUTATHERA. Recommended dose modifications of LUTATHERA in the case of adverse reactions are provided in Table 1.

Table 1 – Recommended Dose Modifications of LUTATHERA for Adverse Reactions

Adverse Reaction	Severity of Adverse Reactions	Dose Modification
Thrombocytopenia (see 7 Warnings and Precautions)	Grade 2 (Platelets < 75 to 50 x 10^9/L)[1] Grade 3 (Platelets < 50 to 25 x 10^9/L) Grade 4 (Platelets < 25 x 10^9/L)	Withhold dose until complete or partial resolution (Grade 0 to 1). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3 or 4 thrombocytopenia, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose. Permanently discontinue LUTATHERA for Grade 2 or higher thrombocytopenia requiring a treatment delay of 16 weeks or longer.
	Recurrent Grade 2, 3 or 4 toxicity	Permanently discontinue LUTATHERA.
Anaemia and Neutropenia (see 7 Warnings and Precautions)	Grade 3 (Hb < 8.0 g/dL)[1], transfusion indicated Grade 4 (life threatening consequences) Grade 3 (Absolute Neutrophil Count (ANC) < 1.0 to 0.5 x 10^9/L) Grade 4 (ANC < 0.5 x 10^9/L)	Withhold dose until complete or partial resolution (Grade 0, 1, or 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anaemia or neutropenia, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose. Permanently discontinue LUTATHERA for Grade 3 or higher anaemia or neutropenia requiring a treatment delay of 16 weeks or longer.
	Recurrent Grade 3 or 4 toxicity	Permanently discontinue LUTATHERA.

Adverse Reaction	Severity of Adverse Reactions	Dose Modification
Renal Toxicity (see 7 Warnings and Precautions)	Defined as: • Creatinine clearance less than 40 mL/min[1]; calculate using Cockcroft Gault with actual body weight, or • 40% increase in baseline serum creatinine, or • 40% decrease in baseline creatinine clearance; calculate using Cockcroft Gault with actual body weight	Withhold dose until complete resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete resolution or return to baseline. If reduced dose does not result in renal toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose. Permanently discontinue LUTATHERA for renal toxicity requiring a treatment delay of 16 weeks or longer.
	Recurrent renal toxicity	Permanently discontinue LUTATHERA.
Hepatotoxicity (see 7 Warnings and Precautions)	Defined as: • Bilirubinaemia > 3 times the upper limit of normal (Grade 3 or 4)[2], or • Albuminaemia less than 30 g/L with international normalized ratio (INR) >1.5.	Withhold dose until complete resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete resolution or return to baseline. If reduced LUTATHERA dose does not result in hepatotoxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose. Permanently discontinue LUTATHERA for hepatotoxicity; requiring a treatment delay of 16 weeks or longer.
	Recurrent hepatotoxicity	Permanently discontinue LUTATHERA.

Adverse Reaction	Severity of Adverse Reactions	Dose Modification
Other Non-Haematologic Toxicity	Grade 3 or 4	Withhold dose until complete or partial resolution (Grade 0 to 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose. Permanently discontinue LUTATHERA for Grade 3 or higher toxicity requiring treatment delay of 16 weeks or longer.
	Recurrent Grade 3 or 4 toxicity	Permanently discontinue LUTATHERA.

[1]The same thresholds are also applicable to baseline values at the time of treatment initiation (see 7 Warnings and Precautions)

[2]If same thresholds are seen at baseline treatment initiation to be considered after benefit risk assessment (see 7 Warnings and Precautions)

4.4 Administration

Administer an antiemetic and the recommended amino acid solution prior to LUTATHERA. Do not administer LUTATHERA as an intravenous bolus.

Pre and concomitant medications

1) Cold Somatostatin Analogs

- Before initiating LUTATHERA: Discontinue long-acting somatostatin analogs (e.g., octreotide long-acting release (LAR)) for at least 4 weeks prior to initiating LUTATHERA. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating LUTATHERA (see 9 Drug Interactions).
- During LUTATHERA treatment: Administer Octreotide LAR 30 mg intramuscularly between 4 to 24 hours after each LUTATHERA dose. Do not administer Octreotide LAR within 4 weeks of each subsequent LUTATHERA dose. Short-acting octreotide may be given for symptomatic management during LUTATHERA treatment but must be withheld for at least 24 hours before each LUTATHERA dose.
- Following LUTATHERA treatment: Continue Octreotide LAR 30 mg intramuscularly every 4 weeks after completing LUTATHERA until disease progression or for up to 18 months following treatment initiation.

2) *Pre-Treatment Anti-emetic*
Administer antiemetics with sufficient lead time before the recommended amino acid solution. Please refer to full prescribing information of anti-emetics for administration instructions.

3) *Amino Acid Solution*
For renal protection, initiate an intravenous amino acid solution containing L-lysine and L-arginine (see Table 2 and Table 3) 30 minutes before administering LUTATHERA. The amino acid solution should not be administered in the same arm as LUTATHERA. Continue the infusion during and for at least 3 hours after LUTATHERA infusion. Do not decrease the dose of the amino acid solution if the dose of LUTATHERA is reduced (see 7 Warnings and Precautions).

The amino acid solution can be prepared as a compounded product, in compliance with hospital's sterile medicinal product preparation good practices and according to the composition specified in Table 2.

Table 2 – Composition of the standard amino acid solution

Compound	Amount
L-Lysine HCl	25 g*
L-Arginine HCl	25 g**
Sodium chloride 2.25 mg/mL (0.225%) solution for injection	1 L
**equivalent to 20.0 g lysine* ***equivalent to 20.7 g arginine*	

Alternatively, some commercially available amino acid solutions can be used if compliant with the specification listed in Table 3.

Table 3 – Specification of commercially available amino acid solutions

Item	Specification
L-Lysine HCl content	Between 18 and 25 g*
L-Arginine HCl content	Between 18 and 25 g**
Volume	1 L to 2 L
Osmolarity	< 1,050 mOsmol/L
**equivalent to 14.4 to 20 g lysine* ***equivalent to 14.9 g to 20.7 g arginine*	

Considering the high quantity of amino acids and the significant volume that commercially available solutions may require to meet the above specifications, the compounded solution is considered the medicinal product of choice, due to its lower volume to be infused and lower osmolarity.

Administration Instructions

LUTATHERA is for intravenous use. It is a ready to use radiopharmaceutical medicinal product for single use only.

LUTATHERA must be administered by slow intravenous infusion over approximately 30 minutes, concomitantly with an amino acid solution administered by contralateral intravenous infusion. LUTATHERA must not be injected as a bolus.

Premedication with antiemetics should be administered with sufficient lead time before the start of amino acid solution infusion. Please refer to Table 4.

Table 4 – Administration procedure of antiemetic amino acid solution and LUTATHERA

Administering agents	Start time (min)	Infusion rate (mL/h)	Duration
Antiemetic	With sufficient lead time prior to amino acid solution	as per prescribing information	as per prescribing information
Amino acid solution, either extemporaneously compounded (1 L) or commercial (1 L to 2 L)	0	250 – 500 depending on the volume	4 hours
LUTATHERA with sodium chloride 9 mg/mL (0.9%) solution for injection	30	Up to 400	approximately 30 minutes

The recommended infusion method for administration of LUTATHERA is the gravity method; however, treating healthcare professionals may use other methods deemed appropriate and safe, including the use of infusion pumps, particularly when dose reduction is required (see Table 1). Radiation safety precautions must be considered regardless of the administration method used (see 4 Dosage and Administration).

LUTATHERA should be infused directly from its original container. The vial must not be opened or the solution transferred to another container. During the administration only disposable materials should be used.

The medicinal product should be infused through an intravenous catheter placed in the vein exclusively for its infusion.

Requirements

Storage of the vial

- Either in a container made of polymethyl methacrylate (PMMA), a transparent radioprotection container that allows a direct visual inspection of the vial; or
- In the lead container in which LUTATHERA is delivered.

Room and equipment preparation


- Administration room:
  - The floor and the furniture should be covered with tissue paper to avoid any accidental contamination.
- Medicinal products to be administered:
  - One vial of LUTATHERA;
  - One bag of sodium chloride 9 mg/mL (0.9%) solution for injection (500 mL)
  - Amino acid solution bag(s); and
  - Antiemetics.
- Care supplies and equipment:
  - Two infusion poles;

- One Long needle (recommended 9 – 10 cm, 18 gauge);
- One Short needle (recommended 2.5 cm, 20 gauge);
- Two gravity intravenous infusion sets with a clamp to regulate or stop the flow (one for LUTATHERA, one for amino acid solution administration);
- Two peripheral intravenous plastic catheters;
- One sterile tubing line with a clamp to regulate or stop the flow;
- A pair of tongs (for LUTATHERA vial handling); and
- Calibrated radioactivity measurement system and Geiger counter to monitor the radioactivity of LUTATHERA.

LUTATHERA vial tubing connections procedure (see Figure 1)

- The tubing line should be pre-filled with sodium chloride 9 mg/mL (0.9%) solution for injection and then connected with a venous catheter previously inserted to the patient's arm.
- The infusion set should be connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection and pre-filled by opening the clamp.
- The short needle should be inserted into the LUTATHERA vial, so that it does not touch the radiopharmaceutical solution. This will equilibrate pressure thus reducing any risk of leakage.
- The short needle should be then connected to the pre-filled infusion set.
- The long needle should be connected to the pre-filled tubing line and then inserted into the LUTATHERA vial, so that it touches the bottom of the vial. This will allow for the complete extraction of the radiopharmaceutical solution.
- The flow of the radiopharmaceutical solution should be regulated with the clamps.

Figure 1 – Gravity infusion method – tubing connection scheme



Administration procedure (gravity method)

During the infusion, the flow of sodium chloride 9 mg/mL (0.9%) solution for injection increases the pressure in the LUTATHERA vial, facilitating the flow of LUTATHERA into the catheter inserted in the patient's peripheral vein.

Careful monitoring of the vital signs during the infusion is recommended.

1. Two intravenous plastic catheters should be inserted into patient's peripheral veins, one on each arm.
2. The catheters should be connected to the infusion sets (one for LUTATHERA, one for the amino acid solution).
3. Antiemetic premedication should be administered with sufficient lead time before start of amino acid solution infusion.
4. Administration of the amino acid solution should be initiated 30 minutes before LUTATHERA infusion, with an infusion rate of 250 to 550 mL/h (depending on the solution volume). The amino acid solution should be administered over a 4 hour span. Rates lower than 320 mL/h are not recommended for commercial solutions. In case of severe nausea or vomiting during amino acid solution infusion, an antiemetic of a different pharmacological class can be administered.
5. Radioactivity in the LUTATHERA vial should be measured immediately before infusion using a calibrated radioactivity measurement system.
6. LUTATHERA infusion should start 30 minutes after the beginning of the amino acid solution infusion, with the infusion rate of approximately 400 mL/h (this infusion rate is the reference rate; the infusion should start at a lower rate of < 100 mL/h for the first 5 to 10 minutes and should then be increased depending on the patient's venous status). LUTATHERA should be administered over a 20 to 30 minute time span. Constant intra-vial pressure should be maintained during the entire infusion.
7. LUTATHERA administration should be initiated by opening first the tubing line connected to the patient's peripheral vein, and then, by opening the infusion set connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection. The pole height should be adjusted in order to compensate any increase or reduction of pressure inside the vial. Moving the patient's arm position should be avoided if possible (extreme flexion or extension which could lead to vein compression).
8. The flow of LUTATHERA from the vial to the patient should be monitored during the entire infusion. Soon after the start of the infusion, the radioactivity emission over the patient's thorax should be measured using Geiger counter to verify the presence of LUTATHERA in the bloodstream. Subsequent checks of the radioactivity emission should be performed approximately every 5 minutes at the level of the patient's thorax and vial. During the infusion, the radioactivity emission from the patient's thorax should steadily increase while the one from the LUTATHERA vial should decrease.
9. To ensure complete administration, the LUTATHERA vial should be kept under even pressure. The level of solution in the vial should remain constant during the entire infusion.
   Visual controls of the solution levels should be repeated during the administration by direct visual control (when PMMA container is used) or using a pair of tongs to handle the vial when the lead shipping container is used.
10. The infusion should be stopped once the radioactivity emission from the vial becomes stable for several minutes (or during two consecutive measurements). This is the only parameter to determine the procedure completion. The volume of sodium chloride 9 mg/mL (0.9%) solution for injection necessary to complete the infusion may vary.

11. Total activity administered is equal to the activity in the vial before infusion minus the activity remaining in the vial after the infusion. The measurements should be performed using a calibrated system.

4.7 Instructions for Preparation and Use of Radiopharmaceuticals

Directions for Quality Control

a) Packaging must be inspected for damage, and a survey meter should be used to determine if any radioactive contamination is present. Do not use product if the integrity of the vial is compromised.
b) Visually inspect the product for particulate matter and discolouration under a shielded screen. Do not use if particulates or discolouration are present.
c) Assay the dose in the vial in a suitable dose calibrator.
d) Use aseptic technique and radiation shielding to withdraw LUTATHERA solution.
e) Do not mix LUTATHERA with other intravenous solutions.
f) Measure the amount of radioactivity in the radiopharmaceutical vial with an appropriate and calibrated device prior to administration in order to confirm that the actual amount of radioactivity to be administered is equal to the planned amount at the infusion time. To perform the calculation, also check vial volume on the documentation received with the product. Review the estimated radiation absorbed dose per injection activity for organs and tissues of adult patients following an intravenous dose of LUTATHERA in Table 5 (see 4.8 Radiation Dosimetry).

4.8 Radiation Dosimetry

Dosimetry and pharmacokinetics of lutetium (^{177}Lu) oxodotreotide injection in adults have been studied in a subset of 20 patients enrolled in the Phase III NETTER-1 sub-study, in order to define the pharmacokinetic profile of lutetium (^{177}Lu) oxodotreotide injection and to calculate whole body and organ radiation dosimetry, with particular focus on the absorbed radioactive dose to critical organs (e.g., kidney and bone marrow). The absorbed organ doses based on whole body planar images following the first (n=9) and the second/third (n=11) lutetium (^{177}Lu) oxodotreotide injection administrations were estimated with OLINDA/EXM (Version 1.1, 2005). Absorbed dose to each organ can be influenced by tumour burden. Consequently, the dosimetry is likely influenced by the disease process.

The estimated radiation absorbed doses for adults receiving LUTATHERA are shown below**.**

Table 5 – Estimated Radiation Absorbed Dose for LUTATHERA in adults in NETTER-1 Trial

Organ	Absorbed dose per unit activity Gy/GBq (N=20)		Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy)	
	Mean	SD	Mean	SD
Adrenals	0.037	0.016	1.1	0.5
Brain	0.027	0.016	0.8	0.5
Breasts	0.027	0.015	0.8	0.4
Gallbladder Wall	0.042	0.019	1.2	0.6
Heart Wall	0.032	0.015	0.9	0.4
Kidneys	0.654	0.295	19.4	8.7
Liver*	0.299	0.226	8.9	6.7
Lower Large Intestine Wall	0.029	0.016	0.9	0.5
Lungs	0.031	0.015	0.9	0.4
Muscle	0.029	0.015	0.8	0.4
Osteogenic Cells	0.151	0.268	4.5	7.9
Ovaries**	0.031	0.013	0.9	0.4
Pancreas	0.038	0.016	1.1	0.5
Red Marrow	0.035	0.029	1.0	0.8
Skin	0.027	0.015	0.8	0.4
Small Intestine	0.031	0.015	0.9	0.5
Spleen	0.846	0.804	25.1	23.8
Stomach Wall	0.032	0.015	0.9	0.5
Testes***	0.026	0.018	0.8	0.5
Thymus	0.028	0.015	0.8	0.5
Thyroid	0.027	0.016	0.8	0.5
Total Body	0.052	0.027	1.6	0.8
Upper Large Intestine Wall	0.032	0.015	0.9	0.4
Urinary Bladder Wall	0.437	0.176	12.8	5.3
Uterus	0.032	0.013	1.0	0.4

*N=18 (two patients excluded because the liver absorbed dose was biased by the uptake of the liver metastases)

**N=9 (female patients only)

***N=11 (male patients only)

In patients receiving a cumulative dose of 29.6 GBq (800 mCi), the mean ± SD estimated absorbed dose to tumours was 210 ± 210 Gy (range 7-984 Gy, n=19, excluding a patient outlier).

Dosimetry of lutetium (^{177}Lu) oxodotreotide injection in adolescents has been studied in 8 patients with somatostatin receptor-positive (SSTR+) tumors, including 4 patients with GEP-NETs, (age range: 13 to 16 years) enrolled in the Phase II NETTER-P study (DCO 21 Aug 2023). Dosimetry was collected to validate the extrapolation from adult dosimetry data, to define the pharmacokinetic profile of lutetium (^{177}Lu)

oxodotreotide injection and to calculate whole body and organ radiation dosimetry, with particular focus on the radiation absorbed dose to critical organs (e.g., kidney and bone marrow).

The mean and SD of the estimated radiation absorbed doses for adolescents receiving LUTATHERA are shown in Table 6.

Table 6 – Estimated Radiation Absorbed Dose for LUTATHERA in Adolescents in NETTER-P Trial

Organ	Absorbed dose per unit activity Gy/GBq (N=8[a])		Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy)	
	Mean	SD	Mean	SD
Adrenals	0.045	0.011	1.3	0.3
Brain	0.021	0.006	0.6	0.2
Breasts[b]	0.018	0.006	0.5	0.2
Esophagus	0.024	0.006	0.7	0.2
Eyes	0.021	0.006	0.6	0.2
Gallbladder Wall	0.031	0.011	0.9	0.3
Heart Wall	0.024	0.006	0.7	0.2
Kidneys	0.773	0.288	22.9	8.5
Left Colon	0.265	0.081	7.8	2.4
Liver	0.216	0.231	6.4	6.8
Lungs	0.024	0.006	0.7	0.2
Osteogenic Cells	0.046	0.019	1.4	0.6
Ovaries[b]	0.026	0.007	0.8	0.2
Pancreas	0.027	0.007	0.8	0.3
Pituitary[c]	1.053	0.348	31.2	10.3
Prostate[d]	0.026	0.006	0.8	0.2
Rectum	0.272	0.085	8.0	2.5
Red Marrow (blood)[e]	0.027	0.005	0.8	0.2
Red Marrow (image)[e]	0.055	0.026	1.6	0.8
Right Colon	0.152	0.045	4.5	1.3
Salivary Glands	0.036	0.017	1.1	0.5
Small Intestine	0.046	0.013	1.3	0.4
Spleen	0.733	0.304	21.7	9.0
Stomach Wall	0.027	0.007	0.8	0.2
Testes[d]	0.021	0.005	0.6	0.2
Thymus	0.022	0.006	0.7	0.2
Thyroid	0.022	0.006	0.6	0.2
Total Body	0.042	0.010	1.2	0.3
Urinary Bladder Wall	0.573	0.088	17.0	2.6
Uterus[b]	0.031	0.008	0.9	0.2

[a] Data are pooled for 8 pediatric patients with SSTR+ tumors, including 4 patients with GEP-NETs (DCO 21 Aug 2023).

[b] N = 5 (female patients only).

[c] N = 7 (3 GEP-NET, 4 other SSTR+ tumours). Pituitary dosimetry estimates were only performed when pituitary uptake was clearly observed on the planar images. Due to the small size of the pituitary gland, availability for quantification only from planar images and interference from activity in the nasal mucosa, estimates can be associated with a large uncertainty.

[d] N = 3 (male patients only).

[e] Red marrow dosimetry estimates were determined either using blood radioactivity or by imaging and scaling of a representative region of the lumbar spine.

5 Overdose

Overdose is unlikely with LUTATHERA as this medicinal product is supplied as a "single dose" and "ready to use" product containing a predefined amount of radioactivity. In the case of overdose, an increase in the frequency of adverse reactions related to radiotoxicity is expected.

In the event of administration of a radiation overdose with LUTATHERA, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition or by forced diuresis and frequent bladder voiding during the first 48 hours after infusion. It might be helpful to estimate the effective dose that was applied.

Hematologic monitoring, including white blood cells, platelets, and hemoglobin, and blood chemistry monitoring, including serum creatinine and blood glucose should be performed every week for 10 weeks.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 Dosage Forms, Strengths, Composition, and Packaging

Table 7 – Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form / Strength/Composition	Non-Medicinal Ingredients
Intravenous	Sterile solution for Intravenous Injection 370 MBq/mL at calibration	Acetic acid 0.48 mg/mL Ascorbic acid 2.8 mg/mL Diethylene triamine pentaacetic acid (DTPA) 0.05 mg/mL Gentisic acid 0.63 mg/mL Sodium acetate 0.66 mg/mL Sodium chloride 6.85 mg/mL Sodium hydroxide 0.65 mg/mL

LUTATHERA Injection containing 370 MBq/mL (10 mCi/mL) of lutetium (^{177}Lu) oxodotreotide is a sterile, preservative-free and clear, colourless to slightly yellow solution for intravenous use supplied in a colourless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium (^{177}Lu) oxodotreotide at the time of injection. The solution volume in the vial is adjusted from 20.5 mL to 25 mL to provide a total of 7.4 GBq (200 mCi) ± 10% of radioactivity.

The product vial is in a lead shielded container placed in a plastic sealed container. The product is shipped in a Type A package.

Description

6.1 Physical Characteristics

Lutetium (Lu 177) decays to stable hafnium (Hf 177) with a half-life of 6.647 days, by emitting beta radiation with a maximum energy of 0.498 MeV and photonic radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.4%). The principal radiation emissions are detailed in Table 8.

Table 8 – Radionuclide properties of ^{177}Lu

Radiation Type	Energy (KeV)	Iβ%	Iγ%
β^-	176.5	12.2	
β^-	248.1	0.05	
β^-	384.9	9.1	
β^-	497.8	78.6	
γ	71.6		0.15
γ	112.9		6.40
γ	136.7		0.05
γ	208.4		11.0
γ	249.7		0.21
γ	321.3		0.22

6.2 External Radiation

Table 9 summarizes the radioactive decay properties of ^{177}Lu.

Table 9 – Physical Decay Chart – Lutetium Lu 177 Half-life = 6.647 days

Hours	Fraction Remaining	Hours	Fraction Remaining
0	1.000	48 (2 days)	0.812
1	0.996	72 (3 days)	0.731
2	0.991	168 (7 days)	0.482
5	0.979	336 (14 days)	0.232
10	0.958	720 (30 days)	0.044
24 (1 day)	0.901	1080 (45 days)	0.009

7 Warnings and Precautions

Please see 3 Serious Warnings and Precautions Box.

The product should be administered under the supervision of a healthcare professional who is experienced in the use of radiopharmaceuticals. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.

The radiopharmaceutical product may be received, used and administered only by authorized persons in designated clinical settings. Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of local competent official organizations.

As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.

General

Amino Acid Solution Related Risks

- **Hyperkalemia**

  A transient increase in serum potassium levels may occur in patients receiving arginine and lysine, usually returning to normal levels within 24 hours from the start of the amino acid infusion.

  Serum potassium levels must be tested before each treatment with amino acid solutions. In case of hyperkalemia, patient's history of hyperkalemia and concomitant medication should be checked. Hyperkalemia must be corrected accordingly before starting the infusion.

  In case of pre-existing clinically significant hyperkalemia, a second monitoring prior to amino acid infusion must confirm that hyperkalemia has been successfully corrected. The patient should be monitored closely for signs and symptoms of hyperkalemia, e.g., dyspnea, weakness, numbness, chest pain and cardiac manifestations (conduction abnormalities and cardiac arrhythmias). An electrocardiogram (ECG) should be performed prior to discharging the patient.

  Vital signs should be monitored during the infusion regardless of baseline serum potassium levels. Patients should be instructed to drink substantial quantities of water (at least 1 glass every hour) on the day of infusion to remain hydrated and facilitate excretion of excess serum potassium.

  In case hyperkalemia symptoms develop during amino acid infusion, appropriate corrective measures must be taken. In case of severe symptomatic hyperkalemia, discontinuation of amino acid solution infusion should be considered, taking into consideration the risk-benefit of renal protection versus acute hyperkalemia.

- **Heart Failure**

  Due to potential for clinical complications related to volume overload, specifically with the amino acid solution, care should be taken with use of arginine and lysine in patients with severe heart failure defined as class III or class IV in the NYHA classification (New York Heart Association). Patients with severe heart failure defined as class III or class IV in the NYHA classification should only be treated after careful benefit-risk assessment, taking into consideration volume and osmolality of the amino acid solution.

- **Metabolic Acidosis**

  Metabolic acidosis has been observed with complex amino-acid solutions administered as part of total parenteral nutrition (TPN) protocols. Shifts in acid-base balance alter the balance of extracellular-intracellular potassium and the development of acidosis may be associated with rapid increases in plasma potassium (see 7 Warnings and Precautions).

Carcinogenesis and Genotoxicity

Late-onset myelodysplastic syndrome (MDS) and acute leukaemia (AL) have been observed after treatment with LUTATHERA (see 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest). Patients who may be at increased risk for developing MDS/AL are those who are > 70 years

old, have impaired renal function, have pre-existing cytopenias, or had prior exposure to chemo or radiation therapy.

Contamination

Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices and patient management procedures (see 4 Dosage and Administration).

Endocrine and Metabolism

Neuroendocrine hormonal crises, due to excessive release of hormones or bioactive substance may occur following treatment with LUTATHERA, therefore observation of patients by overnight hospitalization should be considered in some cases (e.g. in patients with poor pharmacologic control of symptoms). Hormonal crisis typically occurred during or within 24 hours following the initial LUTATHERA dose (see 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest).

Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumour-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.

Hematologic

Myelosuppression was observed in the majority of patients treated with LUTATHERA (see 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest). Most of the cytopenic events were mild or moderate and transient. Patients with cytopenia ≥ Grade 2 at baseline are at higher risk of haematologic toxicity during LUTATHERA treatment.

Haematological evaluation of patients must be performed at baseline and prior to every dose of LUTATHERA. Withhold or reduce dose or permanently discontinue LUTATHERA based on severity of cytopenia (see 4.2 Recommended Dose and Dosage Adjustment). Patients with severely impaired haematological function at baseline prior to LUTATHERA therapy should not start treatment (e.g., Hb < 4.9 mmol/L or 8 g/dL, platelets < 75 G/L or 75 x 10^3/mm^3, or leukocytes < 2 G/L or 2000/mm^3).

Hepatic/Biliary/Pancreatic

Hepatotoxicity in patients treated with LUTATHERA was mostly mild and reversible, without requiring inpatient treatment, but rare serious events including hepatic encephalopathy, cholecystitis, cholestasis, hepatic tumour haemorrhage, and necrosis, have occurred but may be due to underlying disease rather than treatment related effect (see 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest).

No dose adjustment is recommended for patients with mild or moderate hepatic impairment. The pharmacokinetic profile and safety of LUTATHERA in patients with severe hepatic impairment has not been studied. Patients with hepatic metastasis or pre-existing advanced hepatic impairment may be at increased risk of hepatotoxicity due to radiation exposure. Administration of LUTATHERA is not recommended in patients with liver impairment with either total bilirubin > 3 times the upper limit of normal or albuminaemia < 30 g/L and INR >1.5.

Monitor transaminases, bilirubin and serum albumin during treatment. Withhold, reduce dose, or permanently discontinue LUTATHERA based on severity of reaction (see 4.2 Recommended Dose and Dosage Adjustment).

Radiation Exposure

LUTATHERA contributes to a patient's overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. The risks of radiation exposure associated with LUTATHERA may be greater in adolescents than in adults due to longer life expectancy. Continued follow-up is recommended for evaluation of long-term effects.

Close contact (less than 1 meter) with other people should be limited for 7 days following an administration of LUTATHERA. For children and/or pregnant women, close contact (less than 1 meter) should be limited to less than 15 minutes per day for 7 days. Patients should sleep in a separate bedroom from other people for 7 days following an administration of LUTATHERA. Patients should sleep in a separate bedroom from children and/or pregnant women for 15 days.

Renal

Renal dysfunction can develop gradually during and after treatment with LUTATHERA. In most patients, the kidney function impairment is mild or subclinical and acute. Cases of chronic renal impairment have been reported in patients several years following treatment with LUTATHERA which were mild in nature and were confirmed by serum/urine analyses (see 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest). Cases of renal failure have occurred 3-36 months following treatment with LUTATHERA.

LUTATHERA is almost exclusively eliminated through the kidneys; therefore, concomitant administration of an amino acid solution containing L-lysine and L-arginine is necessary before, during and after LUTATHERA (see 4.4 Administration) to decrease reabsorption of lutetium (^{177}Lu) oxodotreotide through the proximal tubules and decrease the radiation dose to the kidneys. Do not decrease the dose of the amino acid solution if the dose of LUTATHERA is reduced.

Advise patients to urinate frequently during and after administration of LUTATHERA.

Renal function as determined by serum creatinine and calculated creatinine clearance must be assessed at baseline, during treatment and at least for the first year after treatment. Withhold or reduce dose, or permanently discontinue LUTATHERA based on severity of reaction (4.2 Recommended Dose and Dosage Adjustment).

Patients with baseline renal impairment, urinary tract obstruction, or predisposing risk factors such as diabetes or hypertension may be at greater risk of toxicity.

For patients with mild or moderate renal impairment, careful consideration of the activity to be administered is required due to possibly increased radiation exposure. No dose adjustment is recommended for renally impaired patients with creatinine clearance ≥ 40 mL/min; however, renal function assessments should be performed more frequently. The safety of LUTATHERA in patients with severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault) or end-stage renal disease have not been studied. Patients with creatinine clearance < 40 mL/min should not be treated. For patients with creatinine clearance < 50 mL/min, an increased risk for transient hyperkalemia due to the amino acid solution should also be taken into consideration (See 7 Warnings and Precautions and 4.2 Recommended Dose and Dosage Adjustment).

The pharmacokinetic profile and safety of LUTATHERA in adolescents with baseline renal impairment have not been studied.

Reproductive Health

Pregnancy Testing:

Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA (see 2 Contraindications and 7.1 Special Populations).

Contraception

Females

LUTATHERA can cause fetal harm when administered to a pregnant woman (see 2 Contraindications and 7.1 Special Populations). Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the final dose of LUTATHERA.

Males

Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during and for 4 months following the final dose of LUTATHERA (see 10 Clinical Pharmacology and 16 Non-Clinical Toxicology).

- **Fertility**

  LUTATHERA may cause infertility in males and females. No animal studies were conducted to determine the effects of lutetium (^{177}Lu) oxodotreotide injection on fertility. The recommended cumulative dose of 29.6 GBq (800 mCi) of LUTATHERA results in a radiation absorbed dose to the testis and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy (see 4.8 Radiation Dosimetry and 7.1 Special Populations). Genetic consultation is recommended if the patient wishes to have children after treatment. Cryopreservation of sperm or eggs can be discussed as an option for patients before treatment.

- **Teratogenic Risk**

  Based on its mechanism of action, LUTATHERA can cause fetal harm (see 10 Clinical Pharmacology). There are no available data on the use of LUTATHERA in pregnant women. No animal studies using lutetium (^{177}Lu) oxodotreotide injection have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including LUTATHERA, have the potential to cause fetal harm.

  Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA (see 4 Dosage and Administration).

  Advise females and males of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose (see 7.1 Special Populations).

Sensitivity/Resistance

Cases of hypersensitivity reactions (including isolated severe/life-threatening angioedema events) have been reported in the post-marketing setting in patients treated with LUTATHERA (see 8.5 Post-Market

Adverse Reactions). Clinical signs included swelling of the face and throat, difficulties in breathing. In the event of serious hypersensitivity reactions, treatment with LUTATHERA should be discontinued immediately. Appropriate medications and equipment to manage such reactions should be available for immediate use. Premedicate patients with a history of hypersensitivity reactions to LUTATHERA before subsequent doses.

7.1 Special Populations

7.1.1 Pregnancy

LUTATHERA is contraindicated in patients with established or suspected pregnancy or when pregnancy has not been excluded (see 2 Contraindications). Based on its mechanism of action, LUTATHERA can cause fetal harm (see 10.1 Mechanism of Action). There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium (^{177}Lu) oxodotreotide injection have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including LUTATHERA, have the potential to cause fetal harm. Advise pregnant women of the risk to a fetus.

In the Canadian general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is estimated at 3.85% and 5%, respectively.

7.1.2 Breastfeeding

There are no data on the presence of lutetium (^{177}Lu) oxodotreotide in human milk, or its effects on the breastfed infant or milk production. No lactation studies in animals were conducted. Because of the potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the final dose.

7.1.3 Pediatrics

Pediatrics (< 12 years of age): The safety and efficacy of LUTATHERA have not been established in pediatric patients below 12 years of age.

Pediatrics: Adolescents (12 to < 18 years of age)

The safety and effectiveness of LUTATHERA have been established in pediatric patients 12 to < 18 years of age with unresectable or metastatic, well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NET) with progressive disease. Use of LUTATHERA for this indication is supported by evidence from a study of LUTATHERA in adults with additional safety, pharmacokinetic, and dosimetry data in pediatric patients aged 12 years and older with somatostatin receptor-positive tumors, including 4 pediatric patients with GEP-NETs (see 4.8 Radiation Dosimetry, 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 10.3 Pharmacokinetics).

There was no clinically relevant difference in lutetium (^{177}Lu) oxodotreotide exposure in pediatric patients aged 13 to 16 years versus adult patients (see 10.3 Pharmacokinetics).

7.1.4 Geriatrics

Of the 1325 patients treated with LUTATHERA in clinical trials, 438 patients were 65 years of age and older. The proportion of patients with serious adverse events was similar to that of younger subjects.

However, since increased risk of toxicity has been described in elderly patients (≥ 70 years old), close monitoring to allow for prompt dose modification in this population is advisable.

8 Adverse Reactions

8.1 Adverse Reaction Overview

The data in this overview reflect LUTATHERA exposure in 111 adult patients with advanced, progressive midgut neuroendocrine tumours (NETTER-1). Safety data in Warnings and Precautions section were also based on experience of an additional 22 adult patients participating in a non-randomized pharmacokinetic substudy of NETTER-1 and in a subset of adult patients (811 of 1214) with advanced somatostatin receptor-positive tumours enrolled in ERASMUS (see 7 Warnings and Precautions).

The most serious ADRs reported with LUTATHERA use were: myelosuppression; secondary myelodysplastic syndrome and leukaemia; renal toxicity; hepatotoxicity and neuroendocrine hormonal crisis (see 7 Warnings and Precautions and 8.2 Clinical Trial Adverse Reactions, Adverse Reactions of Special Interest).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of the adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in the clinical trials of another drug.

NETTER-1

The safety data described below are from NETTER-1, which randomized (1:1) patients with progressive, somatostatin receptor-positive midgut carcinoid tumours to receive LUTATHERA 7.4 GBq (200 mCi) administered every 8 to 16 weeks concurrently with a commercial amino acid solution and with long-acting octreotide (30 mg administered by intramuscular injection within 24 hours of each LUTATHERA dose) (n = 111), or high-dose octreotide (defined as long-acting octreotide 60 mg by intramuscular injection every 4 weeks) (n = 112) (see 14 Clinical Trials). Among patients receiving LUTATHERA with octreotide, 79% received a cumulative dose > 22.2 GBq (> 600 mCi) and 76% of patients received all four planned doses. Ten patients (8.9%) in the LUTATHERA arm experienced 12 adverse events that led to dose modification, 14 patients (12.5%) reported 26 adverse events leading to a permanent discontinuation of the LUTATHERA treatment and 3 patients (2.7%) experienced 4 adverse events leading to a dosing delay. Five patients discontinued LUTATHERA for renal-related events and 4 discontinued for haematological toxicities. At the time of the NETTER-1 final analysis, after a median follow-up duration of 76 months in each study arm, the safety profile remained consistent with that previously reported.

The most frequently observed ADRs (≥ 10%) in patients receiving LUTATHERA with octreotide compared to patients receiving high-dose octreotide were: nausea (65% vs 12%); vomiting (53% vs 10%); fatigue (38% vs 26%); and decreased appetite (21% vs 11%).The most common Grade 3-4 adverse reactions occurring with a greater frequency among patients receiving LUTATHERA with octreotide compared to patients receiving high-dose octreotide include: lymphopenia (44%); increased GGT (20%); vomiting (7%); nausea and elevated AST (5% each); and increased ALT, hyperglycaemia and hypokalaemia (4% each).

Table 10 and Table 11 summarize the incidence of adverse reactions and laboratory abnormalities, respectively.

Table 10 – Adverse Reactions Occurring in ≥ 5% (All Grades) of Patients Receiving LUTATHERA with Octreotide in NETTER-1[1]

Adverse Reaction[1]	LUTATHERA and Long-Acting Octreotide (30 mg) (N=111)		Long-Acting Octreotide (60 mg) (N=112)	
	All Grades %	Grades 3-4 %	All Grades %	Grades 3-4 %
Cardiac disorders				
Atrial fibrillation	5	1	0	0
Palpitations	5	0	5	0
Gastrointestinal disorders				
Nausea	65	5	12	2
Vomiting	53	7	10	0
Abdominal pain	26	3	19	3
Diarrhea	26	3	18	1
Abdominal distension	16	0	13	0
Constipation	10	0	5	0
Dyspepsia	6	0	6	0
Flatulence	5	0	5	0
Abdominal pain upper	5	0	2	0
Gastritis	5	1	1	0
General disorders				
Fatigue	38	1	26	2
Peripheral oedema	16	0	9	1
Pyrexia	8	0	3	0
Asthenia	7	1	7	0
Influenza like illness	5	0	4	0
Chest pain	5	0	2	0
Investigations				
Decreased weight	8	1	7	0
Metabolism and nutrition disorders				
Decreased appetite	21	0	11	3
Dehydration	5	2	3	2
Musculoskeletal and connective tissue disorders				
Back pain	13	2	10	0
Arthralgia	11	0	10	0
Pain in extremity	11	0	5	0
Muscle spasms	6	0	2	0

Adverse Reaction[1]	LUTATHERA and Long-Acting Octreotide (30 mg) (N=111)		Long-Acting Octreotide (60 mg) (N=112)	
	All Grades %	Grades 3-4 %	All Grades %	Grades 3-4 %
Musculoskeletal pain	5	0	5	0
Myalgia	5	0	0	0
Neck Pain	5	0	0	0
Musculoskeletal chest pain	5	1	3	1
Nervous system disorders				
Headache	17	0	5	0
Dizziness	17	0	8	0
Dysgeusia	8	0	2	0
Syncope	6	3	3	2
Infections and Infestations				
Urinary tract infection	6	0	6	1
Nasopharyngitis	5	0	5	0
Bronchitis	5	0	3	0
Psychiatric disorders				
Anxiety	12	1	5	0
Renal and urinary disorders				
Renal failure*	13	3	4	1
Radiation-related urinary tract toxicity**	8	0	3	0
Haematuria	6	0	2	0
Respiratory, thoracic and mediastinal disorders				
Cough	11	1	6	0
Dyspnoea	11	0	8	0
Skin and subcutaneous tissue disorders				
Alopecia	12	0	2	0
Vascular disorders				
Flushing	14	1	9	0
Hypertension	12	2	7	2
Hypotension	5	0	2	0
Ear and Labyrinth Disorders				
Vertigo	5	0	1	0

[1] National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

* Includes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotaemia, renal disorder, renal failure, renal impairment

**Includes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence

Table 11 – Laboratory Abnormalities Occurring in ≥ 5% (All Grades) of Patients Receiving LUTATHERA with Octreotide in NETTER-1[*1]

Laboratory Abnormality[1]	LUTATHERA and Long-Acting Octreotide (30 mg) (N=111)		Long-Acting Octreotide (60 mg) (N=112)	
	All Grades %	Grades 3-4 %	All Grades %	Grades 3-4 %
Haematology				
Lymphopenia	90	44	39	5
Anaemia	81	0	55	1
Leukopenia	55	2	20	0
Thrombocytopenia	53	1	17	0
Neutropenia	26	3	11	0
Renal/Metabolic				
Creatinine increased	85	1	73	0
Hyperglycaemia	82	4	67	2
Hypoalbuminaemia	29	0	29	0
Hyperuricaemia	34	6	30	6
Hypocalcaemia	32	0	14	0
Hypokalaemia	26	4	21	2
Hyperkalaemia	19	0	11	0
Hyponatraemia	19	2	18	4
Hypernatraemia	17	0	7	0
Hypoglycaemia	15	0	8	0
Hypercalcaemia	12	0	9	0
Hepatic				
GGT increased	66	20	67	16
Alkaline phosphatase increased	65	5	55	9
AST increased	50	5	35	0
ALT increased	43	4	34	0
Blood bilirubin increased	30	2	28	0

*Values are worst grade observed after randomization

[1]National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

Lymphocytosis was the only other clinically relevant laboratory abnormality observed with LUTATHERA when considering an incidence of < 5% and affecting at least 2 patients.

ERASMUS

Safety data are available from 1214 patients in ERASMUS, an international, single-institution, single-arm, open-label trial of patients with somatostatin receptor-positive tumours (neuroendocrine and other primaries). Patients received LUTATHERA 7.4 GBq (200 mCi) administered every 6 to 13 weeks with or without octreotide. Retrospective medical record review was conducted on a subset of 811 patients to document serious adverse reactions. Eighty-one (81%) percent of patients in the subset received a cumulative dose ≥ 22.2 GBq (≥ 600 mCi). The rates of serious adverse reactions in this section were based on a median follow-up time of more than 4 years.

Table 12 – Serious Adverse Events ≥1% of patients receiving lutetium (^{177}Lu) oxodotreotide in ERASMUS[1,2]

Serious Adverse Event[1]	lutetium (177Lu) oxodotreotide (N=811)[3]
Blood and lymphatic system disorders	
Pancytopenia	10%
Anaemia	5%
Thrombocytopenia	3%
Surgical and medical procedures	
Cholecystectomy	2%
Abdominal cavity drainage	2%
Transfusion	2%
Stent placement	1%
High frequency ablation	1%
Gastrointestinal disorders	
Diarrhea	6%
Abdominal pain	6%
Vomiting	4%
Nausea	4%
Constipation	3%
Ascites	2%
Ileus	1%
Abdominal pain upper	1%
Intestinal obstruction	1%
Melaena	1%
Metabolism and nutrition disorders	
Dehydration	3%
Hypercalcaemia	2%
Respiratory, Thoracic and Mediastinal disorders	
Dyspnoea	3%
Infections and infestations	

Serious Adverse Event[1]	lutetium (177Lu) oxodotreotide (N=811)[3]
Pneumonia	3%
Urinary tract infection	1%
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	
Myelodysplastic syndrome	2%
Metastasis to central nervous system	1%
Vascular disorders	
Hypotension	1%
Cardiac disorders	
Cardiac failure	1%
Myocardial infarction	1%
Investigations	
Weight decreased	1%
Renal and urinary disorders	
Renal failure	1%
Renal impairment	1%
Hepatobiliary Disorders	
Cholelithiasis	1%
Jaundice	1%
Injury and Poisoning	
Fall	1%
General disorders and administration site	
Death	5%
Pyrexia	4%
Malaise	3%
Pain	2%

[1]ERASMUS study collected Serious Adverse Events only

[2]ERASMUS involved delivery of lutetium (^{177}Lu) oxodotreotide in an investigational formulation similar to LUTATHERA

[3]Data in Table 12 is derived from 811 Dutch patients participating in ERASMUS

Serious Adverse Events reported at ≥ 5% incidence were pancytopenia (10.1%), anaemia (5.3%), diarrhea (6.4%), abdominal pain (5.8%).

Adverse Reactions of Special Interest

Myelosuppression (Anaemia, Thrombocytopenia, and Neutropenia) (see 7 Warnings and Precautions)

In the NETTER-1 trial, myelosuppression occurred more frequently in patients receiving LUTATHERA with long-acting octreotide compared to patients receiving high-dose long-acting octreotide (all grades): anaemia (81% vs 54%); thrombocytopenia (53% vs 17%); and neutropenia (26% vs 11%). Most

of the cytopenic events were mild or moderate, and reversible. For those that did not experience full recovery, improvement in grade was noted. In the ERASMUS trial, serious adverse haematologic events were reported: pancytopenia (10.5%); anaemia (5.3%); and thrombocytopenia (3.3%).

The nadir usually occurs 4-6 weeks after the treatment; the toxicity is mild and reverses without supportive treatment within a few weeks of the LUTATHERA dose.

Secondary Myelodysplastic Syndrome and Leukaemia (see 7 Warnings and Precautions)

Treatment with LUTATHERA is associated with increased risk of developing blood cancer. Late-onset myelodysplastic syndrome (MDS) and acute leukaemia (AL) have been observed after treatment with LUTATHERA. In a phase III study (NETTER-1), with a median follow-up time of 76 months in the main study, MDS was reported in 3 patients (2 patients from the main study and 1 patient from the dosimetry sub-study) (2.3%) who received LUTATHERA and octreotide LAR compared to no patients who received high-dose octreotide LAR. In the ERASMUS trial, 16 patients (2%) developed MDS and 4 patients (0.5%) developed acute leukaemia. The median time to onset was 29 months (9 to 45 months) for MDS and 55 months (32 to 125 months) for acute leukaemia.

Renal Toxicity (see 7 Warnings and Precautions)

Renal dysfunction can develop gradually during and after treatment with LUTATHERA. In ERASMUS, 8 patients (1%) developed renal failure 3 to 36 months following LUTATHERA. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis. In NETTER-1, acute kidney injury was reported in 2.7% of LUTATHERA treated patients, including one Grade 5 event.

Hepatotoxicity (see 7 Warnings and Precautions)

In NETTER-1, treatment emergent serious adverse events of hepatic encephalopathy, hepatocellular injury, cholecystitis, and cholestasis were reported in 4 patients (3.6%). In ERASMUS, 2 patients (0.25%) were reported to have hepatic tumour haemorrhage, oedema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis.

Neuroendocrine Hormonal Crisis (see 7 Warnings and Precautions) Hormonal crisis occurred in 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Two (0.25%) patients were reported to have hypercalcaemia.

Adverse reactions related to amino-acid co-infusion

The amino acid infusion contributes to some adverse reactions described for the LUTATHERA safety profile. Adverse reactions possibly related to the co-infusion of amino acids during LUTATHERA treatment are nausea, vomiting, and transient increased heart rate (see 7 Warnings and Precautions).

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

The safety in adolescent patients was evaluated in the NETTER-P study, a phase II, multicenter, open-label, single-arm study enrolling adolescent patients 12 to < 18 years of age. Safety data are available from 9 patients with somatostatin receptor-positive tumors, including 4 patients with GEP-NETs treated with 4 doses of LUTATHERA of 7.4 GBq (200 mCi), one dose every 8 weeks (±1 week), co-administered with an amino acid solution of 2.5% arginine and 2.5% lysine (DCO 21 Aug 2023). Adolescent patients with GEP-NET received a median of 3 doses (range 2-4 doses) of LUTATHERA and were followed up for safety for a median of 6.21 months (range 2.1-10.6 months). The adverse reactions observed in adolescents were similar to those observed in adult patients treated with LUTATHERA. There was no clinically relevant difference in lutetium (^{177}Lu) oxodotreotide exposure in pediatric patients aged 13 to

16 years versus adult patients (see 10.3 Pharmacokinetics). The long-term safety of LUTATHERA in adolescent patients has not been established.

8.3 Less Common Clinical Trial Adverse Reactions

Other clinically relevant treatment emergent adverse events occurring with LUTATHERA with an incidence of < 5% and affecting at least 2 patients include:

Gastrointestinal Disorders: ascites, dry mouth, abdominal discomfort, stomatitis, dysphagia, rectal haemorrhage, small intestinal obstruction.

General Disorders and Administration Site Conditions: injection site pain, injection site reaction, non-cardiac chest pain, administration site pain, chills, chest discomfort, general physical health deterioration, swelling.

Investigations: electrocardiogram QT prolonged, protein urine.

Metabolism and Nutrition Disorders: hypomagnesaemia, Vitamin D deficiency.

Musculoskeletal and Connective Tissue Disorders: bone pain, flank pain.

Nervous System Disorders: lethargy, parosmia, somnolence, tremor, paraesthesia.

Infections and Infestations: respiratory tract infection, diverticulitis, Clostridium difficile infection.

Vascular Disorders: hot flush.

Respiratory, Thoracic, and Mediastinal Disorders: pleural effusion, wheezing, dysphonia.

Blood and Lymphatic System Disorders: pancytopenia.

Psychiatric Disorders: insomnia, depression, confusional state, sleep disorder, agitation, delirium, panic attack.

Renal and Urinary Disorders: proteinuria, urinary incontinence, dysuria, nephrolithiasis, calculus uretic.

Skin and Subcutaneous Tissue Disorders: rash, pruritus, erythema, dry skin.

Cardiac Disorders: Angina pectoris.

Injury, Poisoning and Procedural Complications: fall, contusion, ligament sprain, femur fracture.

Neoplasms Benign, Malignant and Unspecified (including Cysts and Polyps): malignant neoplasm progression.

Hepatobiliary Disorders: cholestasis.

Eye Disorders: diplopia.

Endocrine Disorders: hypothyroidism, Diabetes mellitus, secondary hypothyroidism.

Ear and Labyrinth Disorders: tinnitus.

Reproductive System and Breast Disorders: gynaecomastia.

Immune System Disorders: hypersensitivity.

Other treatment-emergent adverse events occurring with LUTATHERA with an incidence of < 1% and affecting more than one patient include:

Blood and Lymphatic System Disorders: leukopenia, bone marrow failure, febrile neutropenia.

Cardiac Disorders: atrial fibrillation, tricuspid valve incompetence, angina pectoris, arrhythmia, bradycardia, cardiomyopathy, sinus tachycardia.

Endocrine Disorders: carcinoid crisis, carcinoid syndrome.

Gastrointestinal Disorders: haematemesis, abdominal discomfort, small intestinal obstruction, subileus, gastrointestinal haemorrhage, abdominal pain lower, gastric haemorrhage, gastric perforation, ileus paralytic, inguinal hernia, Mallory-Weiss syndrome, pancreatitis.

Surgical and Medical Procedures: enterostomy, cytoreductive surgery, gastrointestinal tube insertion, pancreaticoduodenectomy, therapeutic embolization, tricuspid valve replacement, tumour excision, abscess drainage, knee arthroplasty, mastectomy, radiotherapy, splenectomy, bile duct stent insertion, gallbladder operation, gastrointestinal surgery, hepatectomy, hepatic embolization, pancreatectomy, venous stent insertion, brain tumour operation, cardioversion, catheter placement, colectomy, coronary angioplasty, coronary arterial stent insertion, duodenal sphincterotomy, hip arthroplasty, hospitalization, intestinal anastomosis, intestinal operation, lymphadenectomy, nephrostomy, polypectomy, pulmonary valve replacement, renal stone removal, Salpingo-oophorectomy, stent removal, thoracic cavity drainage.

General Disorders and Administration Site Conditions: peripheral oedema, oedema, asthenia, chest pain, fatigue, device occlusion, chills, gait disturbance, general physical health deterioration, local swelling.

Hepatobiliary Disorders: cholangitis, cholecystitis, cholestasis, hepatic failure, hepatic function abnormal, hyperbilirubinaemia, cholecystitis acute, bile duct stenosis, hepatic pain.

Immune System Disorders: hypersensitivity.

Infections and Infestations: infection, sepsis, urosepsis, cystitis, device related infection, gastroenteritis, abdominal abscess, cholecystic infective, Herpes zoster, influenza, localized infection.

Investigations: blood bilirubin increased, blood alkaline phosphatase increased, endoscopic retrograde cholangiopancreatography, haemoglobin decreased, hepatic enzyme abnormal, biopsy bone marrow, colonoscopy, diagnostic procedure, hepatic enzyme increased, liver function test abnormal.

Metabolism and Nutrition Disorders: cachexia, decreased appetite, hyponatraemia, hypoglycaemia, Diabetes Mellitus, hypocalcaemia, hypokalaemia, tumour lysis syndrome, hyperglycaemia, hypoalbuminaemia, hypophagia, malnutrition.

Musculoskeletal and Connective Tissue Disorders: back pain, flank pain, musculoskeletal pain, pain in extremity.

Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps): acute myeloid leukaemia, acute leukaemia, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, malignant neoplasm progression, metastases to liver, metastatic pain, tumour pain, metastases to bone, neoplasm progression, prostate cancer, tumour compression.

Injury, Poisoning and Procedural Complications: hip fracture, wound dehiscence, wrist fracture, ankle fracture, clavicle fracture, fat embolism, rib fracture, road traffic accident, upper limb fracture.

Nervous System Disorders: dizziness, syncope, transient ischaemic attack, cerebral infarction, epilepsy, headache, somnolence, cerebral haemorrhage, cerebrovascular accident, cerebrovascular disorder, spinal cord compression.

Psychiatric Disorders: delirium, disorientation.

Renal and Urinary Disorders: hydronephrosis, haematuria, renal disorder, urinary retention, acute kidney injury, urinary incontinence.

Respiratory, Thoracic and Mediastinal Disorders: pleural effusion, pulmonary embolism, cough, epistaxis, haemoptysis, pneumothorax.

Vascular Disorders: haemorrhage, flushing, thrombosis, embolism, deep vein thrombosis.

Congenital, Familial and Genetic Disorders: exomphalos.

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics

The adverse reactions observed in adolescents were similar to those observed in adult patients treated with LUTATHERA (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics).

8.5 Post-Market Adverse Reactions

Adverse drug reactions from spontaneous reports (frequency not known)
The following adverse drug reactions have been derived from post-marketing experience with LUTATHERA via spontaneous case reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

Immune system disorders: Angioedema

9 Drug Interactions

9.2 Drug Interactions Overview

Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Some evidence exists that corticosteroids can induce down-regulation of SST2 receptors. The following recommendations should therefore be taken into account.

9.4 Drug-Drug Interactions

The drugs listed below are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Somatostatin Analogs

Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended (see 4.4 Administration).

Corticosteroids

Some evidence exists that corticosteroids can induce down-regulation of SST2 receptors. As a caution, repeated administration of high doses of glucocorticosteroids should be avoided during LUTATHERA therapy. Patients with history of chronic glucocorticosteroids use should be carefully evaluated for sufficient SST2 receptor expression. It is not known if there is interaction between glucocorticosteroids

used intermittently for prevention of nausea/vomiting during LUTATHERA therapy. Glucocorticosteroids should be avoided as preventative antiemetic treatment.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 Clinical Pharmacology

10.1 Mechanism of Action

Lutetium (^{177}Lu) oxodotreotide binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumours, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighbouring cells.

10.2 Pharmacodynamics

Lutetium Lu 177 exposure-response relationships and the time course of pharmacodynamics response are unknown. At the concentration used (about 10 µg/mL in total, for both free and radiolabeled forms), the peptide oxodotreotide does not exert any clinically relevant pharmacodynamic effect.

In vitro metabolism studies and plasma protein binding studies performed on lutetium (^{175}Lu) oxodotreotide showed an absence of significant inhibitory or induction effects on human CYP450 enzymes, no potential P-gp specific interactions, absence of significant inhibitory effects on human transporters, and that lutetium (^{175}Lu) oxodotreotide is not a highly-protein bound compound. Therefore, LUTATHERA has a low risk for clinically relevant other drug-drug interactions due to metabolism or protein transporter mechanisms.

Cardiac Electrophysiology

The ability of LUTATHERA to prolong the QTc interval at the therapeutic dose was assessed in an open label study in 20 patients with somatostatin receptor-positive midgut carcinoid tumours. No clinically relevant changes in the mean QTc interval (i.e., > 20 ms) were detected.

A transient increased heart rate in patients treated with LUTATHERA and commercial amino acid solution was observed.

10.3 Pharmacokinetics

The pharmacokinetics (PK) of lutetium (^{177}Lu) oxodotreotide injection was characterized in 20 patients with progressive, somatostatin receptor-positive neuroendocrine tumours. The PK parameters are shown in Table 13.

Table 13 – Summary of LUTATHERA Pharmacokinetic Parameters in Patients with Progressive Somatostatin Receptor-Positive Neuroendocrine Tumours

	C_{max} (ng/mL)	T_{max} (h)	$t_{½}$ (h)	$AUC_{0-\infty}$	CL (L/h)	Vz (L)
Single Dose Mean	10 ± 5	0.48 ± 0.26	71.2 ± 28.1	41.3 ± 14.7	4.5 ± 1.4	460 ± 246

*Mean ±SD values are shown. C_{max} = the value of the maximum blood concentration; T_{max} = time after start of infusion at which C_{max} is found; Vz= distribution volume during the terminal phase; CL = clearance; $t_{1/2}$ = terminal half-life

Distribution

The mean volume of distribution for lutetium (^{177}Lu) oxodotreotide is 460 L (CV 54%).

Within 4 hours after administration, lutetium (^{177}Lu) oxodotreotide distributes in kidneys, tumour lesions, liver, spleen, and, in some patients, pituitary gland and thyroid. The co-administration of amino acids reduced the median radiation dose to the kidneys by 47% (34% to 59%) and increased the mean beta-phase blood clearance of lutetium (^{177}Lu) oxodotreotide by 36%.

The non-radioactive form of lutetium (^{177}Lu) oxodotreotide is 43% bound to human plasma proteins.

Elimination

The mean clearance (CL) is 4.5 L/h (CV 31%) for lutetium (^{177}Lu) oxodotreotide. The mean (± standard deviation) effective blood elimination half-life is 3.5 (± 1.4) hours and the mean terminal blood half-life is 71 (±28) hours.

Metabolism

Lutetium (^{177}Lu) oxodotreotide does not undergo hepatic metabolism.

Based on the analysis of urine samples of 20 patients included in NETTER-1 phase III dosimetry, pharmacokinetic and ECG sub-study, lutetium (^{177}Lu) oxodotreotide is poorly metabolized and is excreted mainly as intact compound by renal route.

Excretion

Lutetium (^{177}Lu) oxodotreotide is primarily eliminated renally with cumulative excretion of 44% within 5 hours, 58% within 24 hours, and 65% within 48 hours following LUTATHERA administration. Prolonged elimination of lutetium (^{177}Lu) oxodotreotide in the urine is expected; however, based on the half-life of lutetium 177 and terminal half-life of lutetium (^{177}Lu) oxodotreotide, greater than 99% will be eliminated within 14 days after administration of LUTATHERA (see 7 Warnings and Precautions).

Special populations and conditions

Pediatrics: Adolescents (12 to < 18 years of age)

Safety and efficacy of lutetium (^{177}Lu) oxodotreotide in adolescents were established based on extrapolation from adult data with additional population pharmacokinetic and dosimetry modeling demonstrating that age and body weight had no clinically meaningful effect on the pharmacokinetics and dosimetry of lutetium (^{177}Lu) oxodotreotide. Therefore, the exposure of lutetium (^{177}Lu) oxodotreotide was expected to be similar between adults and adolescents (see 4 Dosage and Administration).

Pharmacokinetic data were collected from 9 adolescent patients with somatostatin receptor-positive tumors, including 4 patients with GEP-NETs, enrolled in the NETTER-P study using the adult dosage (DCO 21 Aug 2023). The pharmacokinetic parameters in adolescent patients were estimated using population pharmacokinetic modeling and showed a mean AUCinf of 35.2 ng.h/mL (CV 12.0%), a mean CL of 6.2 L/h (CV 10.4%) and a mean Cmax of 10.4 ng/mL (CV 4.4%), which occurred at the end of the LUTATHERA infusion (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics). The estimated pharmacokinetic parameters in adolescents were within the range of values in adults.

11 Storage, Stability and Disposal

Store between 2 to 27 °C in the original lead shielding packaging.

The shelf-life is 72 hours. Discard appropriately at 72 hours.

12 Special Handling Instructions

Radiopharmaceuticals should be received, used, administered and disposed of only by authorized persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of the competent official organization.

Lutetium-177 for LUTATHERA may be prepared using two different sources of stable nuclides (either lutetium-176 or ytterbium-176) resulting in different waste management. The user must consult the documentation provided before using LUTATHERA to ensure appropriate waste management.

Always use the principles of time, distance and shielding (reducing the manipulation of the vial and using the material already supplied by the manufacturer) to minimize the radiation dose, especially to the person administering.

Recommended protective measures:

- Use disposable plastic, latex or rubber gloves;
- Wear a lab coat, which must be monitored before leaving the laboratory;
- Wear safety glasses;
- Minimize handling time;
- Use tongs to handle unshielded sources and potentially contaminated vessels;
- Use disposable absorbent liners on trays; and
- Use isolated treatment room

Radiation shielding information:

Physical data[3]

Gamma constant: 0.028 mrem/h per mCi at 1.0 m [7.636E-6 mSv/h per MBq at 1.0 m]

Specific Activity: 1.1E5 Ci/g [4.1E15 Bq/g] max

Shielding:


Photons*
Lead [Pb] Half Value Layer [HVL]: 0.6 mm
Tenth Value Layer [TVL]: 2.1 mm
Betas
Plexiglas Half Value Layer [HVL]: 0.135 cm

(*Photons calculated based on maximum beta energy; assume beta range = 159 mg/cm^2 & Plexiglas density = 1.18 g/cm^3)

Part 2: Scientific Information

13 Pharmaceutical Information

Drug Substance

Non-proprietary name of the drug substance:	lutetium (^{177}Lu) oxodotreotide injection
Chemical name:	lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic (2-7) disulfide
Molecular formula and molecular mass:	$C_{65}H_{87}N_{14}O_{19}S_2{}^{177}Lu$, 1609.6 g/mol
Structural formula:	
Physicochemical properties:	Lutetium (^{177}Lu) decays to stable hafnium (^{177}Hf) with a half-life of 6.647 days, by emitting β^- radiation with a maximum energy of 0.498 MeV and photonic radiations (γ) of 0.208 MeV (11.0%) and 0.113 MeV (6.4%).

Product Characteristics:

LUTATHERA Injection containing 370 MBq/mL (10 mCi/mL) of lutetium (^{177}Lu) oxodotreotide is a sterile, preservative-free and clear, colourless to slightly yellow solution for intravenous use supplied in a colourless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium (^{177}Lu) oxodotreotide at the time of injection. The solution volume in the vial is adjusted from 20.5 mL to 25 mL to provide a total of 7.4 GBq (200 mCi) ± 10% of radioactivity. The final pH is 4.5 to 6.0.

The product vial is in a lead shielded container placed in a plastic sealed container. The product is shipped in a Type A package.

14 Clinical Trials

14.1 Clinical Trials by Indication

Unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease

The safety and efficacy of LUTATHERA were examined in two clinical studies in adult patients as described in Table 14 below.

Table 14 – Summary of Adult Patient Demographics for Clinical Trials with LUTATHERA in GEP-NETs

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex (male/ female)
NETTER-1	Randomized, multicenter, open-label, active controlled phase III study in patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumours	**LUTATHERA arm:** 4 LUTATHERA administrations x 200 mCi each (7.4 GBq) i.v. q8 weeks and long-acting octreotide 30 mg every 4 weeks **Control arm**: high-dose long-acting octreotide 60 mg every 4 weeks	116 LUTATHERA arm 113 control arm	64.0 (28-84) 65.0 (34-87)	63/53 53/60
ERASMUS	Phase I/II open, non-randomized, single arm study to evaluate the efficacy and safety of lutetium (^{177}Lu) oxodotreotide treatment in somatostatin receptor-positive GEP-NETs	lutetium (^{177}Lu) oxodotreotide*: 4 x 200 mCi (7.4 GBq) i.v. every 6-13 weeks	1214 360** - 183 midgut - 133 pancreatic - 19 bronchial - 13 hindgut 12 foregut (other than bronchial and pancreatic)	59.0 (16-90) 60.0 (30-85)	658/556 183/177

*Note, the drug product used for the ERASMUS study used the same active pharmaceutical ingredient as LUTATHERA, but the formulation was slightly different.

**A total of 360 patients with long-term follow-up and baseline tumour assessment had GEP-NET tumours (midgut 183, pancreatic 133, bronchial 19, hindgut 13, foregut other than bronchial and pancreatic 12).

NETTER-1 Study

The efficacy of LUTATHERA in adult patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumours was established in NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial. Key eligibility criteria included Ki67 index ≤ 20%, Karnofsky performance status ≥ 60, confirmed presence of somatostatin receptors on all lesions (OctreoScan uptake ≥ normal liver), creatinine clearance ≥ 50 mL/min, no prior treatment with peptide receptor radionuclide therapy (PRRT), and no prior external beam radiation therapy to more than 25% of the bone marrow.

At the time of the primary analysis, two hundred twenty-nine (229) patients were randomized (1:1) to receive either LUTATHERA 7.4 GBq (200 mCi) every 8 weeks for up to 4 administrations (maximum cumulative dose of 29.6 GBq (800 mCi)) or high-dose long-acting octreotide (defined as 60 mg by intramuscular injection every 4 weeks). Patients in the LUTATHERA arm also received long-acting octreotide 30 mg as an intramuscular injection 4 to 24 hours after each LUTATHERA dose and every 4 weeks after completion of LUTATHERA treatment until disease progression or until week 76 of the study. Patients were co-infused with a commercial amino acid solution. Long-acting octreotide was withheld for at least 4 weeks before each LUTATHERA dose. Patients in both arms could receive short-acting octreotide for symptom management; however, short-acting octreotide was withheld at least 24 hours before each LUTATHERA dose. Randomization was stratified by OctreoScan tumour uptake score (Grade 2, 3 or 4) and the length of time that patients had been on the most recent constant dose of octreotide prior to randomization (≤ 6 or > 6 months). The major efficacy outcome measure was progression-free survival (PFS) as determined by a blinded independent radiology committee (IRC) per RECIST v1.1. Additional efficacy outcome measures were overall response rate (ORR) by IRC, duration of response, and overall survival (OS).

Demographic and baseline disease characteristics were balanced between the treatment arms. Of the 208 patients, whose race/ethnicity was reported, 90% were White, 5% were Black, and 4% were Hispanic or Latino. The median age was 64 years (28 to 87 years); 51% were male, 74% had an illial primary, and 96% had metastatic disease in the liver. The median Karnofsky performance score was 90 (60 to 100), 74% received a constant dose of octreotide for > 6 months and 12% received prior treatment with everolimus. Sixty-nine percent of patients had Ki67 expression in ≤ 2% of tumour cells, 77% had CgA > 2 times the upper limit of normal (ULN), 65% had 5-HIAA > 2 times ULN, and 65% had alkaline phosphatase ≤ ULN. Efficacy results for NETTER-1 are presented in Table 15, Figure 2, and Figure 3.

At the time of the primary PFS analysis (24 July 2015), the number of centrally confirmed disease progressions or deaths was 27 events in the LUTATHERA arm, and 78 events in the high-dose octreotide LAR arm. The median PFS was not yet reached at the cut-off date in the LUTATHERA arm, while for the high-dose octreotide LAR arm the median PFS was 8.5 months (hazard ratio of 0.21 [95% CI: 0.13, 0.32]), indicating a 79% reduction in the risk of disease progression or death in favour of the LUTATHERA arm.

Table 15 – Efficacy Results of Study NETTER-1 (cut-off date 24 July 2015)

Primary Endpoints	LUTATHERA and octreotide LAR N=116	High-dose octreotide LAR N=113
PFS by IRC		
Events (%)	27 (23%)	78 (69%)
Progressive disease, n (%)	15 (13%)	61 (54%)
Death, n (%)	12 (10%)	17 (15%)
Median in months (95% CI)	NR[c] (18.4, NE)	8.5 (6.0, 9.1)
Hazard ratio[a] (95% CI)	0.21 (0.13, 0.32)	
P-Value[b]	< 0.0001	
ORR by IRC		
ORR, % (95% CI)	13% (7%, 19%)	4% (0.1%, 7%)

Primary Endpoints	LUTATHERA and octreotide LAR N=116	High-dose octreotide LAR N=113
Complete response rate, n (%)	1 (1%)	0
Partial response rate, n (%)	14 (12%)	4 (4%)
P-Value[d]	0.0148	
Duration of response, median in months (95% CI)	NR (2.8, NE)	1.9 (1.9, NE)

[a]: Hazard ratio based on the unstratified Cox model


[b]: Unstratified log rank test

[c]: Median follow-up 10.5 months at time of primary analysis of PFS (range: 0 to 29 months)

[d]: Fisher's Exact test


NR: Not reached; NE: Not evaluable

Figure 2 – Kaplan-Meier Curves for Progression-Free Survival in NETTER-1 (cut-off date 24 July 2015)



At the time of the final OS analysis, which occurred 5 years after the last patient randomized (N=231, 117 patients randomized to the LUTATHERA arm and 114 patients randomized to the high-dose octreotide arm, cut-off date 18 January 2021), the median follow-up duration was 76 months in each study arm. There were 73 deaths in the LUTATHERA arm (62.4%) and 69 deaths in the high-dose octreotide LAR arm (60.5%). In the final OS analysis, there was no statistically significant difference in OS between the two treatment arms. The OS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 18 January 2021 is depicted in Figure 3.

Figure 3 – OS Kaplan-Meier curves for patients with progressive midgut carcinoid tumors - cut-off date 18 January 2021 (NETTER-1 phase III study; FAS, N=231)



Number of subjects at Risk

(a) 117	98	79	63	48	35	25	10	0
(b) 114	84	61	45	33	25	21	6	0

ERASMUS Study

The efficacy of LUTATHERA in adult patients with foregut, midgut, and hindgut GEP-NETs was assessed in the ERASMUS study. LUTATHERA was initially provided under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. A subsequent LUTATHERA-specific protocol written eight years after study initiation did not describe a specific sample size or hypothesis testing plan but allowed for retrospective data collection. A total of 1214 patients received LUTATHERA in ERASMUS, of which 360 were patients with GEP-NET, had baseline tumour assessment and long-term follow-up. LUTATHERA 7.4 GBq (200 mCi) was administered every 6 to 13 weeks for up to 4 doses concurrently with the recommended amino acid solution. The major efficacy outcome was investigator-assessed ORR. The median age in the efficacy subset was 60 years (30 to 85 years), 51% were male, 71% had a baseline Karnofsky performance status ≥ 90, 51% had progressed within 12 months of treatment, and 7% had received prior chemotherapy. Fifty two percent (52%) of patients received a concomitant somatostatin analog. The median dose of LUTATHERA was 29.6 GBq (800 mCi).

The investigator ORR is an aggregate of the best overall response (BOR) in 5 subtypes of GEP-NETs; hence, it should be interpreted with caution. Out of the 360 subjects, 19 subjects had bronchial tumours, 133 had pancreatic tumours, 12 had foregut tumours, 183 had midgut tumours, and 13 had hindgut tumours. Subjects had their tumours assessed using either the RECIST 1.1 criteria (145 subjects, 40%) or the SWOG assessment which was retrospectively algorithmically converted to RECIST 1.1 (215 subjects, 60%). The overall investigator assessed ORR was 45% (95% CI; 40, 50), median DOR was 22.9 months (95% CI: 17, 25). The observed ORR was highest for pancreatic NET patients (61%, 95% CI: 52, 69) and lowest for midgut NET patients (33%, 95% CI: 27, 41). In the subset of 145 patients who were evaluated by the investigators using RECIST criteria, the ORR was 41% (95% CI; 33, 50), and median DOR was 35 months (95% CI: 17, 38), and in the subset of 215 patients who were evaluated by the investigators using the converted SWOG criteria, the ORR was 47% (95% CI; 41, 54), and median DOR was 18.5 months (95% CI: 15, 24).

Table 16 – Best Response, ORR and DOR Observed in the Erasmus Phase I/II Study in Dutch Patients with GEP and Bronchial NETs – (FAS, N=360)†

	N	CR		PR		SD		ORR				DOR (months)		
Tumour type		**n**	**%**	**n**	**%**	**N**	**%**	**n**	**%**	**95%CI**		**Median**	**95%CI**	
GEP-NET‡	360	11	3%	151	42%	183	51%	162	45%	40%	50%	23	17	25
Bronchial	19	0	0%	7	37%	11	58%	7	37%	16%	62%	27*	2	ND
Pancreatic	133	7	5%	74	56%	47	35%	81	61%	52%	69%	23	17	33
Foregut**	12	1	8%	6	50%	4	33%	7	58%	28%	85%	NR*	15	ND
Midgut	183	3	2%	58	32%	115	63%	61	33%	27%	41%	18	15	24
Hindgut	13	0	0%	6	46%	6	46%	6	46%	19%	75%	18*	6	ND

CR = Complete response; PR = Partial response; SD = Stable disease; ORR = Objective response (CR + PR);
DOR = Duration of response; ND = Not Detected; NR = Not Reached

†Results are based on subjects that either had assessments using the RECIST criteria or the SWOG converted criteria.

‡Includes Foregut, Midgut and Hindgut;

*The sample sizes for bronchial, foregut, and hindgut DOR entries are small and therefore the results are less reliable;

**Foregut NETs other than bronchial and pancreatic

15 Microbiology

No microbiological information is required for this drug product.

16 Non-Clinical Toxicology

General Toxicology:

- An acute toxicity study was conducted in female rats using a non-radioactive form of lutetium (^{177}Lu) oxodotreotide (lutetium (^{175}Lu) oxodotreotide). The compound was given intravenously, as a bolus, to three groups of three animals each at increasing doses (1.2, 4.8, and 20.5 mg/kg, respectively) at an administration volume of 5 mL/kg. The administered doses were about 40, 170, and 700 fold the recommended human dose. Animals were observed for 11 to 14 days after the treatment.

  The results of the study showed that the compound was well tolerated after single i.v. administration, without inducing any toxicity signs, up to the highest tested dose. Therefore, the Maximum Tolerated Dose (MTD) in female rats is higher than 20.5 mg/kg.

- In the maximum tolerated dose (MTD) study conducted in male and female dogs, lutetium (^{175}Lu) oxodotreotide formulation was administered intravenously, as a bolus, at ascending doses from 0.4 to 3.2 mg/kg (0.4, 0.8, 1.6, and 3.2 mg/kg, that is about 50 to 400 fold the recommended human dose) to a group of 1 male and 2 female dogs, and as single doses of 6.4 mg/kg and 10 mg/kg (about 800 and 1200 fold the intended human dose) to two groups of 1 male and 1 female dog each. The administration volume was 2.5 mL/kg. Animals were observed for a 13 to 15 day period following administration.

  The results of this MTD study in dogs show that intravenous bolus of lutetium (^{175}Lu) oxodotreotide did not induce mortality and any evident drug-related signs of toxicity in male and female Beagle dogs, except for soft to liquid faeces observed on the days following treatment at all doses, and

spread red (at 0.4 to 3.2 mg/kg) or dark red (at 6.4 and 10 mg/kg) areas on the mucosa of the gastro-intestinal tract (jejunum, duodenum or rectum). No changes on haematology, coagulation and clinical chemistry parameters were observed. Based on the results of this study, the doses chosen for the repeated dose toxicity study in dogs were 0.08, 0.5, and 3.2 mg/kg.

- In the repeat dose toxicity study in rats lutetium (^{175}Lu) oxodotreotide formulation was administered intravenously at 1.25, 5, or 20 mg/kg (that is, 40, 170, and 700 fold the recommended human dose) for four times, once every two weeks, to mimic the schedule applied in human but with a reduced time between treatments to increase the possibility of occurrence of any toxic effects linked to the non-radioactive compound. The treatment groups were composed of 10 male and 10 female rats. The study included additional animals (5 males and 5 females) administered with the vehicle and with the highest dose, in order to study the reversibility, persistence or delayed occurrence of toxic effects for 3 months post-treatment.

  The compound induced no mortality and no major signs of toxicity. The primary target organ was the pancreas, a high SSTR2 expressing organ. Pancreatic acinar apoptosis occurred at lutetium (^{175}Lu) oxodotreotide intermediate and high doses (≥ 5 mg/kg). These findings were consistent with high uptake of the peptide in the pancreas in animal biodistribution studies.

  Therefore, the NOEL corresponds to 1.25 mg/kg, that is around 40 times the human dose.

- A repeated dose toxicity study was also conducted in dogs. Lutetium (^{175}Lu) oxodotreotide formulation was administered intravenously four times, once every two weeks, at three different doses (0.08, 0.5, and 3.2 mg/kg, corresponding to about 10, 65, and 400 fold the recommended human dose).

  The compound induced no mortality and no major signs of toxicity at any dose tested. The signs observed (salivation, vocalisation and soft to liquid faeces, associated at the highest dose to slight increase in body temperature and a slight decrease of food consumption) were mild and reversible. As for rats, the primary target organ was the pancreas. Moderate and reversible pancreatic acinar apoptosis occurred in few animals at doses ≥ 0.5 mg/kg.

  At recovery sacrifice there was no incidence of pancreatic acinar apoptosis in the 4 male dogs of the control group and male dogs of group treated with the highest dose. In female dogs there was a single case of pancreatic acinar apoptosis in highest dose group and also in the control group, both at minimal degree, confirming the reversible nature of this change.

  Acinar apoptosis was the only histological change observed in the high dose group. Therefore, considering also the reversibility of this change after recovery, 3.2 mg/kg was considered to be the NOAEL in the repeated dose toxicology study in dogs, which is equivalent to 400 times the human dose.

Genotoxicity:

As with other radiopharmaceuticals which distribute intracellularly, there may be increased risk of chromosome damage from Auger electrons if nuclear uptake occurs.

Lutetium (^{175}Lu) oxodotreotide formulation was examined for the ability to induce gene mutations in tester strains of *Salmonella typhimurium* and *Escherichia coli*, as measured by reversion of auxotrophic strains to prototrophy. The five tester strains TA1535, TA1537, TA98, TA100 and WP2 uvrA were used. Experiments were performed both in the absence and presence of metabolic activation, using liver S9 fraction from rats.

Lutetium (^{175}Lu) oxodotreotide formulation was also assayed for its ability to induce mutations (5-trifluorothymidine resistance) in L5178Y TK+/- mouse lymphoma cells after *in vitro* treatment, in the absence and presence of S9 metabolizing system, using a fluctuation method.

These genotoxicity studies showed that lutetium (^{175}Lu) oxodotreotide formulation does not induce mutation at the TK locus of L5178Y mouse lymphoma cells *in vitro*, nor reverse mutation in *Salmonella typhimurium* or *Escherichia coli* in the absence or presence of S9 metabolic activation.

Carcinogenicity:

No long-term animal studies have been performed to evaluate carcinogenic potential of LUTATHERA. However, radiation is a carcinogen and mutagen.

Reproductive and Developmental Toxicology:

No long-term animal studies have been performed to evaluate whether LUTATHERA affects fertility in males and females.

Special Toxicology:

The effects of lutetium (^{175}Lu) oxodotreotide on blood pressure, heart rate, body temperature and electrocardiogram (duration of PR, PQ, QT and QRS) were investigated in dogs after a single intravenous administration. The compound did not show any effect on cardiac conduction times or body temperature and did not cause arrhythmia at the doses tested (from 0.08 to 0.8 mg/kg).

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

LUTATHERA®

lutetium (^{177}Lu) oxodotreotide injection

This Patient Medication Information is written for the person who will be taking **LUTATHERA®.** This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about LUTATHERA**,** talk to a healthcare professional.

Serious warnings and precautions box

- LUTATHERA should be used by healthcare professionals who are appropriately trained in use of radiopharmaceuticals.
- Kidney impairment can occur in patients treated with LUTATHERA. Tell your healthcare professional about any kidney condition prior to receiving LUTATHERA.
- Secondary blood cancer (myelodysplastic syndrome or acute leukaemia) can rarely occur several years after you have completed LUTATHERA treatment.

What LUTATHERA is used for:

LUTATHERA is a radiopharmaceutical medicine used for

- The treatment of adults and adolescents (12 years of age and older) with certain tumours (gastroenteropancreatic neuroendocrine tumours) that have somatostatin receptors, which cannot be completely removed from your body by surgery, have spread in your body (metastatic) and no longer responds to your current treatment.

How LUTATHERA works:

The tumour needs to have certain proteins (somatostatin receptors) on the surface of its cells in order for the medicine to work. LUTATHERA binds to these receptors, delivering radioactivity directly to the tumour cells, causing their death.

The use of LUTATHERA involves exposure to radioactivity. Your healthcare professional and the nuclear medicine healthcare professional have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweighs the risk due to radiation.

The ingredients in LUTATHERA are:

Medicinal ingredient: lutetium (^{177}Lu) oxodotreotide.

Non-medicinal ingredients: acetic acid (to adjust acid content); ascorbic acid (for stability); diethylene triamine pentaacetic acid (DTPA) (removes unwanted chemical substances from the solution); gentisic acid (for stability); sodium acetate (to adjust acid content); sodium chloride (adjusts concentration of the substances in the product); sodium hydroxide; and water for injection (see Other warnings you should know about “LUTATHERA contains sodium”).

LUTATHERA comes in the following dosage forms:

Solution for intravenous injection, 370 MBq/mL. MBq is a measure of radioactivity.

Do not use LUTATHERA if:

- You are allergic to lutetium (^{177}Lu) oxodotreotide or to any of the other ingredients in this medicine;
- You are pregnant; and/or
- Your kidneys are seriously impaired.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take LUTATHERA. Talk about any health conditions or problems you may have, including if:

- You are under 12 years of age.
- You are pregnant or plan to become pregnant. Exposure to radiation during pregnancy may harm your unborn baby. Women who are able to become pregnant should use effective contraception and avoid getting pregnant during treatment with LUTATHERA and for 7 months after your last dose of LUTATHERA.
- You are a male with a female partner of childbearing age. Male patients should use effective birth control during treatment and for at least 4 months after completing treatment.
- You are breastfeeding or plan to breastfeed. It is not known if LUTATHERA passes into your breast milk. Breast feeding must be stopped. If treatment with LUTATHERA during breast feeding is necessary, the child must be weaned.
- You have mild to moderate chronic kidney disease.
- You suffer from urinary incontinence (uncontrollable urination).
- You have a kidney or urinary tract abnormality, including urinary track obstruction.
- You have mildly altered blood cell counts. LUTATHERA can lead to a decrease in the number of your red blood cells (responsible for transporting the oxygen from the lungs to the different organs), platelets (cells that help the blood to clot), and other blood cells such as white blood cells (helps to fight infection). Before starting treatment and before each subsequent treatment, your healthcare professional will perform blood tests. Depending on the results of these tests, your healthcare professional will decide if the treatment can be started, can be continued, or needs to be adjusted, postponed or discontinued.
- You have altered liver function.
- You have a history of hyperkalemia.
- You have a history of heart disease.
- You previously received anti-cancer treatment (chemotherapy, radiation therapy)
- You have previously received any radionuclide therapy (therapy with a radioactive medicine)
- You had any other type of cancer within the last 5 years.

Other warnings you should know about:

LUTATHERA contains sodium.

This medicine contains 0.14 mmol (3.2 mg) of sodium per mL. To be taken into consideration by patients on controlled sodium diet.

Pediatric Patients (12 to <18 years of age)

LUTATHERA can be used in adolescents between the ages of 12 and 18 years at the same dose as for adults. Care should be taken when LUTATHERA is used in patients between the ages of 12 and 18 years

with kidney disease. The risks of radiation exposure associated with LUTATHERA may be greater in adolescents than in adults due to longer life expectancy. Continued follow-up is recommended for evaluation of long-term effects. The long-term safety of LUTATHERA in adolescent patients has not been established.

The safety and efficacy of this medicine have not been established in children under 12 years of age.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with LUTATHERA:

- Somatostatin analogues (drugs similar to LUTATHERA) – you may be asked to stop and/or adapt your treatment for a short period of time while receiving LUTATHERA.
- Corticosteroids – inform your healthcare professional if you are taking corticosteroids.

How to take LUTATHERA:

- LUTATHERA will be administered intravenously (into a vein in your arm) under the supervision of a healthcare professional who is experienced in the use of radiopharmaceuticals.
- There are strict laws on the use, handling and disposal of radiopharmaceutical products like LUTATHERA. It will only be used in special controlled areas. Your healthcare professional will inform you when you can leave the controlled area or hospital.

Usual dose:

For adults and adolescents aged 12 to 18 years, the recommended dose of LUTATHERA is 7.4 GBq (gigabecquerel, the unit used to express radioactivity), administered as a single infusion into your vein every 8 weeks, for a total of 4 doses.

In addition to the LUTATHERA injection, an infusion with amino acids (substances present in many foods and in muscles) will be given to you in order to protect your kidneys. This might cause nausea and vomiting; you will also receive an injection before the start of treatment to reduce these symptoms.

Duration of the procedure:

Your healthcare professional will inform you about the usual duration of the procedure. The LUTATHERA infusion takes approximately 30 minutes; but the complete administration procedure will take approximately 5 hours.

Treatment monitoring:

Treatment with LUTATHERA can have an impact on blood cells, liver and kidneys. Your healthcare professional will ask you to have regular blood tests in order to detect any side effects as early as possible. Based on the results, your healthcare professional may decide to delay or stop your treatment with this medicine.

After administration of LUTATHERA:

You will be requested to drink a sufficient amount of water (1 glass every hour) necessary to urinate every hour on the day of infusion and the day after. Try to defecate every day, use a laxative if necessary. These steps are needed to help remove the medicine from your body.

Because this medicine is radioactive, you will have to follow the instructions described below to minimize radiation exposure to others.

General rule

You must avoid close contact (less than 1 meter) with people who live with you and should try to keep a distance of at least one meter for 7 days after you receive LUTATHERA. When together for a prolonged period, a distance of 2 meters or more should be maintained.

Use of toilets

Toilets must be used in a seated position, even for men. It is absolutely necessary to use toilet paper each time. It is also important to wash your hands to avoid contaminating the door handles.

Contact with children and pregnant women

It is strongly recommended to limit close contact (less than 1 meter) with children and/or pregnant women to less than 15 minutes per day for 7 days after you receive each dose of LUTATHERA.

Contact with spouse and people in the family circle

During 7 days after LUTATHERA administration, sleep in separate bedroom from other people. For children and/or pregnant women, extend this time to 15 days.

People who need extra assistance

People who are confined to bed or have reduced mobility will preferably receive assistance by a care provider. It is recommended that when providing assistance in the bathroom, the care provider wears disposable gloves for 7 days after administration. In the case of the use of special medical equipment such as catheters, colostomy bags, bedpan, water nozzle, or anything that could be contaminated by your body fluids, these must be emptied immediately in the toilet and then cleaned. If anyone helps you clean up vomit, blood, urine, or stool they should wear plastic gloves. The gloves should then be disposed of in a specific trash plastic bag (according to "Trash recommendations" below).

Dishes and bathroom accessories

Take special precautions during the 7 days after treatment:

- Flush all wipes and/or toilet paper down the toilet immediately after use;
- Always wash your hands well after using the toilet;
- Take a shower every day;
- Flush any tissues or any other items that contain anything from your body, such as blood, urine and faeces down the toilet. Items that cannot be flushed down the toilet, such as menstrual pads and bandages, must be placed in specific trash plastic bags (according to "Trash recommendations" below); and
- Wash your underwear, pyjamas, sheets and any clothes that contain sweat, blood or urine separately from the laundry of other members of your household, using a standard washing cycle. You do not need to use bleach and do not need extra rinses.

Trash recommendations

Keep the specific plastic trash bags separated from the other trash. Keep the bags away from children and animals.

A member of the hospital staff will tell you how and when to get rid of these trash bags.

Hospitalisation and emergency care

If for any reason you require emergency medical assistance or an unplanned hospitalisation during the 3 months after your treatment, you should inform the medical providers that you have been treated

with LUTATHERA. You should carry your discharge letter with you at all times, so that you can provide information on the reason for use, date and dose of LUTATHERA.

Travel

Keep your discharge letter with you whenever you are travelling for at least 3 months after treatment.

Other precautions

The nuclear medicine healthcare professional will inform you if you need to take any other special precautions after receiving this medicine. Contact your nuclear medicine healthcare professional if you have any questions.

Overdose:

An overdose is not expected because of how LUTATHERA is packaged and administered. However, in the case of an overdose, you will receive the appropriate treatment.

If you think you, or a person you are caring for, have taken too much LUTATHERA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you miss an appointment to receive LUTATHERA, contact your nuclear medicine healthcare professional as soon as possible to reschedule.

Possible side effects from using LUTATHERA:

These are not all the possible side effects you may have when taking LUTATHERA. If you experience any side effects not listed here, tell your healthcare professional.

Very common side effects (may affect more than 1 in 10 people):

- Nausea, vomiting (usually during the first 24 hours)
- Abdominal pain, abdominal bloating (abdominal distension)
- Diarrhea
- Fatigue (possibly delayed for more than 24 hours after treatment)
- Decreased appetite
- Pain (including back pain, arms, legs, joints, chest, bone, side, muscles or neck)
- Headache
- Dizziness (vertigo)
- Fluid retention, swelling (usually in the legs)
- Flushing
- Increase in blood pressure (hypertension)
- Anxiety
- Hair loss (alopecia)
- Cough
- Trouble breathing (dyspnoea)
- Decrease in blood cell counts, red blood cells (anaemia), white blood cells (leukopenia or lymphopenia or neutropenia), platelets (thrombocytopenia), pancytopenia (decrease in multiple blood cell types)

- Change in blood test results: increased creatinine, increased or decreased blood sugar, decreased albumin, increased uric acid, increased or decreased calcium, increased or decreased sodium, increased or decreased potassium, increased liver enzyme levels, increased bilirubin

Common side effects (may affect between 1 in 100 and up to 1 in 10 people):

- Constipation
- Indigestion (dyspepsia), gas (flatulence)
- Sore mouth (stomatitis)
- Weakness, lack of energy (lethargy)
- Fever, chills, influenza-like illness
- Injection site pain, injection site reaction
- Allergic reaction (hypersensitivity)
- Muscle spasms, shaking (tremor)
- Tingling sensation (paraesthesia)
- Weight loss
- Dehydration, dry mouth
- Disturbed sense of taste, disturbed sense of smell
- Sleepiness (somnolence), trouble sleeping (insomnia)
- Fainting/loss of consciousness (syncope), falls
- Sprains, fractures
- Low blood pressure (hypotension)
- Hot flush
- Rash, skin itching and redness, dry skin
- Bruising (contusion)
- Wheezing or “high-pitched whistling sound”
- Change in voice (dysphonia)
- Depression
- Agitation
- Panic attack
- Double vision (diplopia)
- Ringing in the ears (tinnitus)
- Kidney stones
- Breast growth in men (gynecomastia)
- General decline in physical health
- General feeling of discomfort, illness, abnormal or uneasiness (malaise)
- Change in blood cell counts: increased lymphocyte count
- Change in blood test results: decreased magnesium, decreased vitamin D
- Difficulty swallowing (dysphagia)
- Death due to disease progression or underlying comorbidities

Uncommon side effects (may affect up to 1 in 100 people):

- Disturbance in walking
- Confusion (disorientation)
- Delirium
- Malnutrition

Not Known (frequency cannot be estimated from the available data):

- Facial/throat swelling and/or difficulty breathing (signs and symptoms of angioedema)

During LUTATHERA treatment, you may also have surgical/medical procedures

Common

- Blood transfusion

Uncommon

- To drain fluid from the peritoneal cavity, the space between the abdominal wall and organs (abdominal cavity drainage)
- To filter your blood to rid your body of harmful wastes, extra salt, and water (dialysis)
- To place a stent
- To drain abscess
- For gastrointestinal tube insertion
- To harvest (collect) stem cells from your bone marrow (bone marrow harvest)
- To remove polyps from the inside of the colon, also called large intestine (polypectomy)

LUTATHERA contributes to your overall long-term cumulative radiation exposure (the amounts of radiation that an individual typically receives from different sources over a longer period of time). Long-term cumulative radiation exposure may increase your risk for developing new cancers and increase the chances for your future children to have hereditary (from a parent) abnormalities. LUTATHERA has been associated with an increased risk for blood cancers.

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
Very common			
Anaemia (decreased red blood cells): weakness, paleness, shortness of breath, headaches, dizziness, heart palpitations		√	√
Thrombocytopenia (low level of blood platelets), **lymphopenia, neutropenia, leukopenia** (low level of white blood cells), **pancytopenia** (low level of blood cells): unusual bruising, more bleeding than usual after injury, fever, catching infections more frequently		√	√
Kidney problems • renal failure: changes in urine output, changes in urine colour, changes in blood test results		√	√
Liver changes: changes in liver enzyme levels in the blood		√	√
Common			
Heart problems • atrial fibrillation, palpitations (irregular heartbeat), shortness of breath, chest pain • angina pectoris: crushing chest pain		√	√

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
• myocardial infarction (heart attack): chest pain, pain in arms, neck, jaw, shoulder, shortness of breath, sweating • cardiac failure: shortness of breath, swelling in legs, ankles, and feet, cough, wheezing			
Stomach and gastrointestinal problems • gastritis: abdominal pain or bloating, vomiting, indigestion • ascites: fluid buildup in the abdomen • intestinal obstruction : constipation, cramps, vomiting • rectal bleeding • diverticulitis (inflammation of the intestine): abdominal pain, fever, nausea • clostridium difficile infection: watery diarrhea and fever		√	√
Liver, gall bladder, and bile duct problems • cholestasis (reduced bile flow): yellow eyes or skin • cholecystitis (inflamed gallbladder): upper abdominal pain • gallstones: upper abdominal pain • jaundice: yellowing of eyes and skin		√	√
Urinary problems • infection: frequent urination, urgency, blood in the urine, incontinence		√	√
Kidney problems: kidney swelling		√	√
Respiratory problems • nasopharyngitis: stuffy nose, sore throat, fever, aches • bronchitis: cough, fever, aches • pneumonia (lower respiratory tract infection): chest pain, fever, cough • pleural effusion: shortness of breath, chest pain when breathing deeply		√	√
Thyroid problems • hypothyroidism • secondary hypothyroidism (underactive thyroid gland): weakness, fatigue, changes in thyroid blood tests		√	√

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
Diabetes mellitus: (increased blood sugar levels): excessive thirst, high urine output, increased appetite with weight loss		√	√
Cancer progression and other cancers • blood cancers, myelodysplastic syndrome • acute leukaemia: feeling tired, dizzy, weak, shortness of breath, pale skin, infections and abnormal bleeding		√	√
Neuroendocrine hormonal crisis, carcinoid syndrome: flushing, diarrhea, low blood pressure, difficulty breathing usually within 24 hours of LUTATHERA dose		√	√
Uncommon			
Other gastrointestinal problems • gastrointestinal tract tears: bleeding, lower abdominal pain • inguinal hernia: painful bulge on either side of pelvic bone • blood in stools, vomiting or coughing blood, ileus (slowed intestinal movement): cramping, feeling full, constipation • inflamed pancreas: abdominal pain that radiates into the back, nausea, vomiting, and fever		√	√
Other liver problems including • liver failure (jaundice): yellowing of skin and eyeballs, upper abdominal pain, nausea • hemorrhagic ascites (build up of fluid containing blood in the abdomen)		√	√
Blood clotting problems • clots in a vein: pain, swelling • clots in lungs: shortness of breath, chest pain, cough • stroke (clotting or bleeding in the brain)		√	√
Other heart problems • heart valve problems, heart muscle problems: fatigue, swelling in the abdomen, legs, shortness of breath		√	√
Herpes zoster (viral infection): painful rash		√	√
Spinal cord compression: pain, numbness, or weakness in arms, hands, legs or feet		√	√
Tumour compression		√	√
Impaired wound healing		√	
Collapsed lung: sudden chest pain and shortness of breath		√	√

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
Weakening of umbilical cord		√	√
Not known			
Angioedema: facial/throat swelling and/or difficulty breathing		√	√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

If you want more information about LUTATHERA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html; the manufacturer's website https://www.novartis.ca or by calling 1-800-363-8883.

This leaflet was prepared by Novartis Pharmaceuticals Canada Inc.

Date of Authorization: 2026-10-23

LUTATHERA is a registered trademark